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1 INTRODUCTION 
 
One of the major reasons for failure of a leading compound in drug development 
process is poor pharmacokinetic qualities. MDR1 transporter is in a significant position 
to influence the absorption, distribution and/or elimination (ADME) of a drug due to its 
wide distribution on the apical membranes of the body. In order to have a therapeutic 
effect, the drug has to reach the systemic blood circulation. The extent of absorption 
from the intestine depends on the dissolution, passive permeability and susceptibility of 
a drug to MDR1 efflux and/or CYP3A4 metabolism in the intestine.   
 
Clinically significant drug-drug interactions have risen to be a concerning issue for drug 
safety. Therefore it is of great importance to predict a drug’s potential to either cause 
interactions or be susceptible to them. Oral administration of a drug causes a high level 
of exposure in the intestine and concentrations higher than the resulting plasma 
concentrations. For this reason, the possibility for transporter saturation is more 
significant in the intestine. In addition, already low doses of an MDR1 inhibitor may 
cause drug-drug interactions in the intestine rather than in other sites. As MDR1-
mediated efflux can limit the absorption of substrate drugs, inhibitors of MDR1 may 
enhance the absorption markedly. Absorption may also vary due to inter-individual 
variation in the expression of MDR1. Thus, being a substrate for MDR1 the drug is 
exposed to limited absorption, MDR1-mediated drug-drug interactions and high inter-
individuality in pharmacokinetics.  
 
High throughput in vitro assays are frequently applied for screening of substrates for 
MDR1. However quantifying the extent to which intestinal absorption is affected by 
MDR1or the extent of a drug-drug interaction in vivo in humans is particularly 
challenging. The principal obstacle has been the limited ability to appropriately scale 
the preclinical data into the in vivo situation. The extent to which in vitro data can 
predict in vivo situation needs more investigation and significant in vitro-in vivo 
correlations would greatly increase the value of in vitro studies (del Amo et al., 2009). 
This requires reliable, reproducible and suitable preclinical in vitro and in vivo animal 
data from standardized experiments. In silico physiologically based pharmacokinetic 
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modeling has been utilized to demonstrate MDR1’s contribution on absorption in 
humans using in vitro data. Nevertheless standardized methods for predicting intestinal 
drug-drug interactions have not yet been established (Tachibana et al., 2010) 
 
 
2 ROLE OF MDR1 IN PHARMACOKINETICS 
 
2.1 Physiological function and tissue distribution 
 
MDR1 (multidrug resistance 1 protein), also known as P-glycoprotein, was originally 
identified over-expressed in tumor cells showing resistance to cancer treatment (Juliano 
and Ling 1976). MDR1 belongs to the ABC (ATP-binding cassette) transporter 
superfamily and is encoded by gene ABCB1. The ABC superfamily of transporters uses 
adenosine triphosphate (ATP) as an energy source to the transfer of substrates out of the 
cell against the concentration gradient (Schinkel and Jonker 2003). MDR1 is the most 
studied efflux transporter, found located mainly on the apical membranes of the body. 
MDR1 is widely distributed, including brush border membrane of intestinal enterocytes, 
capillary endothelial cells in the blood-brain barrier, canalicular membrane of 
hepatocytes, renal proximal tubular cells and placenta (Cordon-Cardo et al. 1990). Due 
to the wide distribution in barrier tissues of the body, MDR1 is suggested to have a 
protective role limiting the bioavailability and exposure of substrate drugs. 
 
MDR1-mediated efflux has been shown to limit oral absorption of drugs and cause 
variable and nonlinear pharmacokinetics (e.g. talinolol (Wetterich et al., 1996)). The 
transport of a drug across the intestinal epithelial depends on its passive permeability 
and the active transporter-mediated efflux. MDR1 is suggested to have a significant 
importance in distribution of drugs. Distribution into the brain across the blood-brain 
barrier has been studied extensively in vivo in mdr1-gene deficient mice and significant 
in vitro-in vivo correlations of the extent of MDR1’s influence have been shown 
(Hakkarainen et al. 2010). MDR1’s location in hepatocytes and renal tubular cells may 
limit the systemic exposure of substrate drugs due to the efflux of drug and metabolites 
into the bile and/or into urine via kidneys.  
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2.2 Structure and mechanism  
 
The 170 kDa MDR1 protein consists of 1280 amino acids. It has two homologous 
halves each containing 6 membrane spanning α-helices (trans-membrane domain; TMD) 
and a nucleotide binding domain (NBD) located in the cytoplasm. MDR1 protein is 
post-translationally modified by phosphorylation and N-glycosylation. Distinctive 
phosphorylation of MDR1 by kinases has been shown to have an influence on MDR1 
activity (Idriss et al., 2000). 
 
MDR1 recognizes a great variety of structurally unrelated compounds that are generally 
of hydrophobic and amphipathic nature, thus partition into the lipid layer. The two 
models most supported as the mechanism of transport are (1) flippase model, where the 
binding site is in the cytosolic (inner) leaflet of the membrane bilayer and drugs are 
translocated to the extracellular (outer) leaflet (Higgins and Gottesman 1992) and (2) 
the hydrophobic vacuum cleaner model, in which drugs are transported from the 
cytosolic leaflet out of the cell into the aqueous phase (Raviv et al., 1990).   
 
2.3 Interindividual variation in MDR1 expression 
 
Involvement of intestinal MDR1 has showed to be a cause of significant interpatient 
variation in the oral bioavailability of substrate drugs (e.g. cyclosporine (Lown et al., 
1997)). Interindividual variability in the expression or function of MDR1 might explain 
the variation in response to drug therapy, at least to some extent, but the genetic 
contribution is still unclear. It has been suggested that ABCB1 gene polymorphisms 
contribute to the variability in MDR1 function. The effect of MDR1 genotypes has been 
studied the most on pharmacokinetics of digoxin, a common substrate for MDR1, with 
modest and conflicting results (Hoffmeyer et al., 2000; Chowbay et al. 2005). Many 
other factors, such as exposure to MDR1 inducing chemicals, age, intestinal 
inflammation and circadian rhythm have been suggested to affect the intestinal MDR1 
expression level (del Amo et al., 2009).  
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There has been extensive research in order to identify correlations between MDR1 
genotypes or haplotypes and mRNA or MDR1 protein expression, activity and related 
drug response. However majority of studies have failed to demonstrate a significant 
associations and the results have been inconsistent (Leschziner et al. 2007). Attempts 
have been made to correlate MDR1 mRNA and protein expression levels as well, but no 
correlation has been found (Berggren et al., 2007; Canaparo et al., 2007). Considerable 
interindividual variability was observed in mRNA levels in the human intestine, 
however even higher interindividual variability was seen in MDR1 protein levels 
(Berggren et al., 2007). It has been suggested that lack of correlation might be due to 
either functional polymorphisms of the MDR1 gene or post-translational mechanisms. 
This emphasizes the importance of determining the MDR1 protein levels instead of the 
mRNA levels, when studying the relationship between MDR1 gene and the clinical 
outcome. 
 
 
3 INFLUENCE OF MDR1 ON ORAL DRUG ABSORPTION 
 
3.1 Factors affecting intestinal drug absorption 
 
3.1.1 Physiological and physicochemical factors 
 
Absorption from the intestine is influenced by physicochemical properties of the drug 
(e.g. solubility, dissolution and permeability) and the physiological factors of the 
gastrointestinal tract. In addition to intestinal transporters and enzymes, physiological 
variables are gastric emptying, small intestine transit time, gastrointestinal pH, intestinal 
blood flow, effects of food, fluids and disease state (e.g. inflammation in the intestine).  
 
3.1.2 MDR1 and CYP3A4 interplay 
 
When studying the extent of drug absorption, besides MDR1 efflux the limiting effect 
of gut metabolism has to be considered. CYP3A4 is the most abundantly expressed 
CYP enzyme in the intestine (Paine et al., 2006). Due to the overlap of substrate 
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specificities between MDR1 and CYP3A4, the effect of each has to be evaluated. 
Moreover an interplay has been proposed. Cummings et al. (2002) suggested that if a 
drug is substantially effluxed by MDR1, it can increase the fraction of drug metabolized, 
since the effluxed drug is reabsorbed, having more time to be metabolized in the 
enterocytes.  Because clinically relevant selective inhibitors of either MDR1 or 
CYP3A4 have not been identified to date, estimation of their effect on intestinal 
absorption of drugs separately is challenging. 
 
3.1.3 Saturation of intestinal MDR1 and CYP3A4 
 
Another consideration is the possible saturation of CYP enzymes and transporters in the 
intestine. For example talinolol has showed saturable kinetics after increasing doses in 
humans (Wetterich et al., 1996). If a drug is identified being a substrate for MDR1, 
further in vitro experiments should be performed using increasing concentrations of the 
drug to evaluate the saturability. If the transporter is saturated at the therapeutic doses, 
its drug bioavailability would increase after the saturation point. However the prediction 
of clinically relevant concentrations, or the local concentration of drug in the intestine 
and correlating the activity of MDR1 in a cell line or mouse intestine to the human 
intestine, is difficult. Due to saturation, it is possible for a clinical dose of MDR1 
substrate to show high fraction absorbed and intestinal availability (FaFg), but in a 
microdose clinical study to show low FaFg. This saturation can be assessed by 
comparing the FaFg values of a clinical dose and a microdose, when possible (Tachibana 
et al., 2010). In silico physiologically based pharmacokinetic modeling can be utilized 
to guide the preclinical studies and predict concentrations in vivo in humans. 
 
3.2 Preclinical methods for studying MDR1-mediated efflux in intestinal absorption 
 
3.2.1 In vitro methods  
 
The in vitro assays for studying MDR1-mediated transport can be classified into (1) 
uptake (2) transport and (3) ATPase assay (Zhang et al., 2003). All assays are suitable 
for screening MDR1 substrates, and in many cases are aimed to identify or classify 
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inhibitors of MDR1 as well. Experimental method that has been applied most frequently 
in studying MDR1’s influence in intestinal absorption is the transport assay. Transport 
assay is the most informative in screening potential transporter-mediated absorption 
issues and the most definite assay to determine the localization of transporters (Zhang et 
al., 2003). The transport assay is also recommended in the FDA draft guidance of drug 
interaction studies (2006) and EMA draft guideline for investigation of drug interactions 
(2010). Cell lines used in the transport assay have to express MDR1 and form a 
confluent, polarized cell monolayer with tight extracellular junctions. Immortalized 
human colorectal carcinoma derived cell line (Caco-2), where MDR1 is naturally 
expressed, has been widely used to measure the bi-directional differences in 
permeability. Also, MDR1-transfected Madine-Darby canine kidney cell line (MDCKII) 
and MDR1-transfected pig-kidney cell line (LLC-PK1) have shown usability due to 
their short culture time and availability of wild type cell lines to use as controls (Zhang 
et al., 2003). Uptake and ATPase assays are described later when the in vitro methods 
for studying MDR1 inhibition are discussed. 
 
3.2.2 In vitro parameters 
 
In transport assay, the flux rate of the drug through the cell monolayer (apparent 
permeability (Papp)), is measured in both apical to basal (A-B) and basal to apical (B-A) 
directions. Most commonly used parameter is the ratio between the B-A and A-B flux 
rates (RB-A/A-B), also called the efflux ratio (ER). Efflux ratio > 2 indicates increased 
transport of the drug to the secretory direction (B-A). To confirm that the efflux activity 
is due to MDR1, a follow-up experiment with a potent and specific MDR1-inhibitor is 
advisable. FDA draft guidance (2006) recommends follow-up experiment for drugs with 
efflux ratio > 2. However, some researchers perform follow-up experiments with 
MDR1-inhibitor for drugs efflux ratios 1.5 - 2 to further investigate MDR1’s 
involvement (Polli et al., 2001; Hubatsch et al., 2007). The efflux of a drug investigated 
should be studied over a range of concentrations (e.g. 1, 10 and 100 µM). 
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3.2.3 In vivo methods  
 
Mdr1 knockout mice have been most widely used in in vivo studies and have greatly 
improved the understanding of MDR1’s physiological function and influence on 
pharmacokinetics. In situ mice and rat intestine perfusion models have been used in 
studying the intestinal absorption of MDR1 substrates. Determination of MDR1 effect 
only on intestinal absorption is more challenging to study in living animals, since first-
pass metabolism in the liver and MDR1’s effect on elimination of the drug have to 
considered. Obviously, in situ models however suffer from the limitation of being an 
isolated organ instead in the living body.  
 
In mice, MDR1 is encoded by mdr1a and mdr1b and mdr2. The genes that confer the 
multidrug-resistance phenotype are mdr1a and mdr1b. It has been reported that an 82 % 
homology exists with human MDR1 and mouse mdr1a, and 75 % homology with 
mdr1b (Gros et al. 1988). The single (mdr1a gene or mdr1b gene) and double (mdr1a 
and mdr1b) knockout strains in mice have shown to be viable, fertile and have no 
apparent physiological abnormalities (Schinkel et al., 1994; Schinkel et al., 1997). Mice 
naturally lacking the expression of mdr1a gene product were detected in a 
subpopulation of a CF-1 mouse strain (Lankas et al., 1997). The advantage is that the 
expression of other mdr1 family gene products is not altered. In mdr1a knockout mouse 
strain, the expression of mdr1b has been shown to increase, but the only murine MDR1 
isoform present in the intestine is mdr1a suggesting that the model can be well utilized 
in studying MDR1’s influence on oral absorption (Schinkel et al., 1994). Nevertheless it 
must be kept in mind that disruption of genes may have compensatory effects and 
species differences exist between animal and human mdr1 gene and MDR1 transporter. 
In addition, extrapolation of MDR1-mediated drug interaction in rodents to humans 
must be conducted with caution. 
 
3.2.4 In vivo parameters 
 
Very good in vivo parameters to describe quantitatively the influence of MDR1 on 
intestinal absorption do not exist. Most common practice has been to compare oral 
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pharmacokinetic parameters between MDR1 knockout and wild type mice. For example 
drug concentration in plasma after oral administration at a certain time point and oral 
AUC (del Amo et al., 2009). Often, both the oral and i.v. AUC values for knockout and 
wildtype mice have not been calculated in pharmacokinetic studies. This information 
would enable the calculations of ratio of oral bioavailability (F). To evaluate the role of 
MDR1 in the intestinal absorption specifically, the knowledge of the drug’s first pass 
elimination is needed. It has to considered that also the distribution and elimination 
parameters may change in MDR1 knowkout animals. 
 
3.3 In vitro in vivo correlations 
 
Troutman and Thakker (2003b) introduced the parameters absorptive quotient (AQ) and 
the secretory quotient (SQ). They showed in their previous study (Troutman and 
Thakker 2003a) that MDR1 has an asymmetric effect on the transport of compounds 
across Caco-2 cell monolayer. Substrates can use different absorptive and secretory 
transport pathways. For substrates that use primarily the transcellular pathway, the 
apparent Km values have differed in absorptive and secretory directions. The parameters 
AQ and SQ would describe directly the attenuation of the absorptive quotient and the 
enhancement of the secretory quotient due to MDR1-mediated efflux. Troutman and 
Thakker proposed that because efflux ratio does not always provide a good estimate of 
the attenuation of intestinal absorption of drugs due to MDR1, the effect of MDR1 on 
absorptive transport alone should be used to assess the effect on intestinal absorption. 
Absorptive flux is measured under normal cell culture conditions and after complete 
inhibition of MDR1 by selective, non-competitive inhibitor (see AQ calculation Table 
1 ). 
 
Collett et al. (2004) showed that a permeability assay in Caco-2 monolayers allows a 
reasonable prediction of the probable in vivo effect of MDR1 on plasma drug levels 
after oral administration. The ratio of A-B permeability measured in the presence and 
absence of a selective MDR1 inhibitor (RGF) (Table 1) in Caco-2 monolayers showed a 
significant correlation (r
2
 = 0.8, p < 0.01) with the ratio of plasma drug levels in the 
absence and presence of MDR1 in mice (RKO/WT in vivo), data obtained from literature. A 
ratio of drug plasma concentrations at a single time point (at 4 h) was used. A strong 
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correlation with RGF was observed also after correction of in vivo ratio with IV data. In 
this study, the more commonly used parameter RB-A/A-B showed no correlation with in 
vivo data (r
2
 = 0.33, p = 0.11). Researchers suggested that RGF would be more reliable in 
predicting in vivo effect of MDR1 from in vitro results. This result was however 
criticized by del Amo et al. (2008) because the plasma drug concentration ratio (without 
IV correction) may be influenced also by distribution or elimination and that the IV 
corrected correlation was established for 6 drugs instead of 9. They also stated that 
because drug concentration-time curves might differ in MDR1 knockout and wildtype 
mice, one should be careful in comparing only one time point. 
 
Still, RA-B/B-A  is the most frequently used in vitro parameter to compare to in vivo mice 
studies of oral absorption (del Amo et al., 2009). Amo et al. reviewed in vitro-in vivo 
correlations and reported that in most cases, when RA-B/B-A was reported ≥2, the ratio 
between mdr-deficient and wildtype mice of different in vivo parameters (drug 
concentration in plasma, AUC oral or oral bioavailability) was higher than 1. 
Importantly, they showed that there is a lack of standard in vivo parameters to describe 
quantitatively the function of MDR1 in absorption. But, as Troutmar and Thakker stated 
(2003a), the parameter RA-B/B-A is affected by both absorptive and secretory flux rates. 
Due to this and the varying passive permeability of drug compounds, it seems that 
determining the ratio of apparent permeability in absorptive direction in absence and 
presence of MDR1-inhibitor (RGF) (or the ratio between A-B flux rates obtained in the 
parental and in MDR1-transfected cell line) or the absorptive quotient (AQ) are more 
appropriate to use in in vitro-in vivo correlations. The total transfer or drugs across the 
cell monolayer is the sum of passive diffusion of the drug and the MDR1-mediated 
efflux. For drugs with high passive permeability, it is likely that active transport by 
MDR1 is a smaller factor in the overall absorption. 
 
Adachi et al. (2003) performed in situ intestinal perfusion experiments for 12 
compounds in mdr1a/1b knockout and in normal mice. The results were compared to 
results from their previous permeability assays, determined by comparing the 
permeability in MDR1-expressing and parental LLC-PK1 monolayers (Adachi et al., 
2001). The parameter obtained was the permeability-surface area (PS) product. PS 
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product is the product of the apparent membrane permeability coefficient and the 
surface area. PS product ratio was further calculated by dividing the PS products in 
mdr1a/1b knockout mice by those in normal mice (Table 1). In vitro PS product ratio 
(PS A-B) was calculated by dividing the PS product (A-B) of parental LLC-PK1 
monolayer by MDR1-expressing monolayer (Table 1). A significant correlation (r = 
0.855, P < 0.01) was observed between the parameters. Adachi et al. suggested that 
drugs with high PS product ratios may be markedly affected by interindividual 
differences in the expression of MDR1 and by coadministered substrates or inhibitors.  
 
Proposed parameters for in vitro – in vivo correlations. 
 Parameter Definition  Reference 
In vitro  RGF 
  
 
Ratio between A-B flux 
rates in the presence 
(Ppass A-B) and absence 
(Papp A-B) of MDR1 
inhibitor 
Collet et al., 2004 
 Absorptive quotient 
(AQ) 
Ratio between (Ppass A-B -  
Papp A-B) and Ppass A-B 
Troutman and Thakker 
2003a 
 PS product ratio (PSA-B) Ratio between PS 
product A-B of 
parenteral monolayer 
and MDR1-expressing 
monolayer 
Adachi et al., 2003 
In situ PS product ratio Ratio between PS 
products of mdr1a/1b 
knockout mice and 
normal mice 
Adachi et al., 2003 
In vivo F, AQin vivo p.o. and i.v. AUC values 
for both knockout and 
wildtype rodents are 
needed 
del Amo et al, 2008; 
Troutman and Thakker 
2003a 
 
3.4 Predicting MDR1’s influence on drug absorption in humans 
 
3.4.1 Physiologically based pharmacokinetic modeling 
 
In physiologically based pharmacokinetic (PBPK) modeling, the pharmacokinetic 
processes (ADME) of a drug are mathematically demonstrated by using physiological 
and anatomical descriptions and physicochemical properties of the drug. In silico PBPK 
modeling can be used as a tool to guide in vitro and in vivo studies and potentially to 
reduce preclinical animal studies. Interspecies differences of transporters have to be 
Table 1.  
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acknowledged when extrapolating animal results to human, but by developing of 
quantitative predictive models this step could potentially be passed. Incorporation of 
MDR1 efflux and CY3A4 metabolism in the model highly improves the significance of 
predictions. In modeling based on in vitro data, important issues are the relevant 
concentration and site of the substrate and what correlation factors are needed to adapt 
the in vitro data (e.g. MDR1 expression and Km parameter). 
 
Yu et al. (1996) introduced the compartmental absorption and transit (CAT) model. In 
the model small intestine is divided into seven compartments, where the absorption 
occurs. Transit of drug through small intestine takes 199 min and follows 1
st
 order 
kinetics (Yu et al., 1996).  
 
In advanced compartmental absorption and transit (ACAT) model (Figure 1) each 
compartment is modeled with accurate physiological information regarding volumes, 
transit time, length and radius (Agoram et al., 2001). Physiochemical concepts, such as 
solubility and permeability are more easily incorporated in the model than the 
expression and activity of transporters and metabolism. Commercial Gastroplus® 
software implements the ACAT model in the simulations. 
 
 
Figure 1. Structure of the ACAT model (Tubic et al., 2006). 
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The advanced dissolution, absorption and metabolism (ADAM) model is a module 
within the Simcyp® Population-Based Simulator (Jamei et al., 2009). It is a version of 
the segregated flow model (Cong et al., 2001), which takes tissue layers and 
distributions in blood supply into account in describing the intestinal absorption. 
ADAM model is however compartmental and based on CAT model. The nine segments 
of the gastrointestinal tract differ in terms of size, abundance of transporters and 
enzymes, transit time, pH and bile salt concentration. ADAM model assumes enterocyte 
a well-stirred compartment, where MDR1 and CYP enzymes compete for the binding of 
a substrate. The interindividual variations can be demonstrated by Simcyp® software.  
 
 
 
 
Figure 2. Structure of the ADAM model (Darwich et al. 2010).The ADAM model is 
compartmental with segregated blood flows to each section.   
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Figure 3. Structure of the ADAM model (Darwich et al. 2010). In the seven 
compartments of the small intestine the drug can dissolve, re-precipitate, be exposed to 
chemical degradation, be absorbed and exposed to transporters and/or metabolizing 
enzymes.  
 
3.4.2 Utility of models in the prediction of absorption in humans 
 
Kwon et al. (2004) simulated (1) whether the effect of MDR1 in oral absorption would 
be significant at clinically relevant concentrations and (2) the role of MDR1 in oral 
absorption modeled by a dynamic CAT model linked to a pharmacokinetic model. In 
the latter simulation, the ratio of transporter mediated transport to passive transport 
(RMDR1) was used to evaluate if MDR1 would reduce the oral bioavailability of drugs 
with high solubility. Both simulations suggested that for high-solubility drugs MDR1 
altered the bioavailability only at low, well below clinically relevant concentrations.  
 
Tubic et al. (2006) demonstrated involvement of MDR1 in nonlinear absorption of 
MDR1-substrate talinolol using the ACAT model. The results predicted from the model 
were then compared to a phase I dose escalation study of talinolol, oral doses increasing 
from 25 to 400 mg. Talinolol is a selective β-1 antagonist, usually administrated 100 mg 
once a day. Talinolol has shown dose-dependent nonlinear absorption, but is 
metabolized only < 1%, allowing the examination of drug efflux without the effect of 
metabolism in the intestine. However, to demonstrate the clinically observed nonlinear 
dose dependence, the experimental Km and Vmax values had to be optimized. The 
optimized Km value (0.69 µM) was lower than the experimental Km (412 µM). The 
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researchers suggested that this may result from the fact that the ACAT model uses the 
simulated concentration of the cytoplasm of the enterocyte for the interaction with 
MDR1, while the concentration of talinolol within the actual binding site (apical leaflet 
of membrane bilayer (Shapiro and Ling 1997) would be expected to be higher because 
of the hydrophobicity of the molecule. Thus, to obtain a good correlation between in 
silico simulations and in vivo data, experimental kinetic parameters Km and Vmax could 
not be used.  
 
Badhan et al. (2009) applied the CAT model in simulating the influence of MDR1 
efflux, CYP3A4 metabolism and passive permeability on drug available for absorption 
within the enterocytes. Preclinical in vitro data was used to model the fraction of drug 
escaping the enterocyte (Fg ), the parameter used to quantify the results. Compounds 
with varying intestinal metabolic and MDR1 efflux clearances were used to develop the 
model. In vitro apparent permeability (PappA-B) was converted to human effective 
permeability (Peff), which was further converted to absorption rate constant (Ka). In vitro 
MDR1 efflux ratios ranging 1-10 were tested to simulate the intestinal efflux. 
Comparison was made to in vivo Fg, which was derived from reported oral 
bioavailability (F = Fa × Fg × Fh), where Fh was estimated from in vivo hepatic clearance 
(CLh), liver blood flow and hepatic extraction ratio, Fa was assumed. The model 
successfully predicted Fg for the range of drugs tested (within 20 % of observed in vivo 
Fg) and demonstrated that incorporation of in vitro efflux ratios may be useful in the 
prediction of Fg involving MDR1 substrates. The presence of MDR1 increased the level 
of CYP3A4 metabolism. Fg was highly sensitive to changes in intrinsic metabolism, but 
less sensitive to changes in intestinal drug permeability. 
 
Darwich et al. (2010) applied the ADAM model to simulate the interplay of transport 
and metabolism in oral drug absorption. Studied variables were the intrinsic clearances 
(CLint) and Km values for MDR1 and CYP3A4. Darwich et al., investigated the effects 
of MDR1 and gut metabolism on Fa and Fg of Biopharmaceutics Classification System 
(BCS) I – IV compounds. An increase in the intrinsic clearance of CYP3A4 (CLint-
CYP3A4) resulted in a marked decrease in Fg.  However, an increase in the intrinsic 
clearance of MDR1 (CLint-MDR1) lead to a marked reduction in Fa. Also a minor decrease 
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in Fg was noticed, and the researchers suggested that it may be a cause of decreased 
enterocytic concentration due to MDR1-mediated efflux and de-saturation of CYP3A4 
enzymes. However the significance of actual interplay of MDR1 and metabolism needs 
further studies, but the model shows feasibility to investigate the relative roles of 
transporters and metabolism in absorption of drugs.  
 
 
4 MDR1-INHIBITION 
 
4.1 Mechanism of inhibition 
 
MDR1 recognizes substrates at the cytoplasmic leaflet of the lipid bilayer (Shapiro and 
Ling 1997). The transporter has at least two binding sites (Dey et al., 1997; Shapiro and 
Ling 1997) that are distinct, but yet dependent (Wang et al., 2000). The binding of a 
substrate at one site of MDR1 is suggested to prevent or lower the affinity for binding at 
the other site. At least, it seems to be evident, that a tight linkage or allosteric effects 
between the nucleotide binding sites and the transport binding sites exists (Wang et al., 
2000). Due to these findings, interaction between MDR1 substrates does not always 
follow simple kinetics. The complexity of the molecular mechanisms of MDR1 
inhibition contributes to the challenge of predicting potential for MDR1-mediated drug-
drug interactions, qualitatively or quantitatively. 
 
The pattern of MDR1 inhibition can be classified into at least three types of mechanism: 
(1) competitive, (2) non-competitive and (3) co-operative interaction (Litman et al, 
1997). In the case of competitive inhibition, two substrates act on the same binding site 
of MDR1 and only one substrate is able to bind at a time. For example the interaction 
between verapamil and cyclosporine is of competitive type (Litman et al, 1997). Km for 
verapamil’s ability to stimulate the ATPase activity (ATP hydrolysis) increases with the 
increasing concentrations of cyclosporine, suggesting weaker affinity. Cyclosporine acts 
as a competitive inhibitor of verapamil transport, but there is evidence that cyclosporine 
can interact with both binding sites of MDR1 (Ayesh et al., 1996). Non-competitive 
inhibition implies that the two substrates are able to bind simultaneously to MDR1 at 
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distinct binding sites. The simplest example is the interaction between verapamil and 
sodium orthovanadate (Na3VO4). Sodium orthovanadate interacts with the ATP binding 
domain of MDR1 instead of the substrate binding sites, inhibiting the ATPase activity 
concentration dependently (Urbatch et al, 1995). The Km of verapamil does not change 
with the sodium orthovanadate concentrations, even though transport is inhibited 
(Litman et al, 1997). When the substrates of MDR1 bind in distinct sites in a non-
competitive manner and allosteric effects are involved in the interaction, the inhibition 
mechanism can be classified as co-operative interaction. 
 
4.2 In vitro methods for studying MDR1 inhibition 
 
In vitro assays for studying inhibition ABC transporter inhibition consist of membrane 
based (ATPase and vesicular transport) and cell based (uptake and transport) assays. 
Advantages of membrane based assays are that the effect of a drug compound on a 
specific transporter can be better examined, while in cell based assays the expression of 
multiple transporters, even in engineered cell lines, has to be considered (Xia et al., 
2007). However the transporter under investigation can be blocked by a selective 
inhibitor, which reveals the effect of the specific transporter on the transport. The 
expression level of the transporter can vary depending on culture conditions and cell 
passages. This has to be taken into account in membrane based assay as well. Another 
advantage of membrane based assays is that when prepared in large amount, membrane 
vesicles can be stored in the freezer, as cells need to be maintained under culture 
condition before use. Membrane based assays are quite easy to conduct, so they are 
generally less labor and time consuming. But because of the intact cell culture, cell 
based assays can provide more definite information about drug and transporter 
interactions. Both membrane and cell based assays can be adapted to high throughput 
mode. Vesicular transport assay and cell based assays can be used to determine kinetic 
parameters for substrates and inhibitors and are considered functional assays. 
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4.2.1 ATPase assay 
 
ABC transporters require ATP hydrolysis as an energy source for the transport of 
substrates out of the cell. ATP hydrolysis yields inorganic phosphate (Pi), which can be 
detected by colorimetric reaction (Sarkadi 1992) (Figure 4). The amount of Pi liberated 
is proportional to the activity of that transporter. ATPase assay is performed by using 
membrane vesicles purified from Spodoptera frugiperda (Sf9) insect or mammalian 
cells, which express high levels of the specific human transporter. A proportion of the 
membrane vesicles are turned inside-out, so that the transporter is located on the outer 
surface of the membrane. In the presence of ATP, the efflux transporter pumps the 
substrate into the membrane vesicle and Pi is generated. ABC transporters show a 
baseline ATPase activity that varies for different transporters and membrane 
preparations. Substrates of the transporter stimulate the baseline ATPase activity and 
inhibitors or slowly transported substrates inhibit the baseline ATPase activity. 
Inhibitors also decrease the ATPase acitivity measured in the presence of a stimulating 
substrate (inhibition mode). Sodium orthovanadate is a specific inhibitor of the ABC 
transporters due to the interaction with the ATP binding domain of transporters.  
Because there is also some endogenous ATP coming from the membrane, the ATPase 
activity of the transporter is calculated as the difference between the amount of Pi 
released in the presence and absence of sodium orthovanadate . 
 
ATPase assay can be used as a screening tool to identify substrates for ABC 
transporters. However, it is not a functional assay and it cannot be used to differentiate 
substrates and inhibitors (FDA draft guidance, 2006). Other limitations of the ATPase 
assay are high intra- and interassay variability and possibility to yield false negatives. 
Substrate has to be tested in wide enough range of concentrations, because the 
stimulation or inhibition can occur at either low or high concentrations. In order to do 
this, the test concentrations cannot be limited by solubility.  
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4.2.2 Vesicular transport assay 
 
Also vesicular transport assay is performed by using purified membrane vesicles. In 
vesicular transport assay, the amount of a substrate transported into the membrane 
vesicles is studied (Figure 5). After incubation with ATP, membrane suspension 
including the substrate and inhibitor is sucked through a filter that retains the membrane 
vesicles. By breaking the vesicles, the substrates transported into the vesicle can be 
collected and measured. An interaction between substrate and inhibitor is detected as a 
change in the initial rate of substrate transport. Compounds may also move across the 
membrane by passive diffusion. Thus, the MDR1-mediated movement is calculated as 
the difference in the uptake of substrate in the presence or absence of ATP. 
 
Vesicular transport assay is a functional assay and can be used to distinguish substrates 
and inhibitors (Szeremy et al., 2011). It is also an effective model to determine kinetic 
parameters. However, for drug compounds with high passive permeability, the assay 
can yield false negatives. Active transport may remain unnoticed, since passive 
diffusion and active transport both may transfer drug into the inside-out vesicles. But 
Figure 4. ATPase assay. ATP hydrolysis yields inorganic phosphate (Pi), which can be 
detected by colorimetric reaction (SOLVO Biotechnology). 
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because the significance of active efflux is likely to be smaller for drugs that have high 
passive permeability, vesicular transport assay is considered valuable in studying 
MDR1 inhibition.  
 
 
 
 
4.2.3 Uptake assay 
 
In this assay the amount of a compound, commonly the acetoxymethyl ester or calcein 
(calcein-AM), accumulated within the cell is measured. Calcein-AM is a very lipid 
soluble, able to rapidly permeate across a cell membrane. From the lipid bilayer, 
calcein-AM can be effluxed back to the medium by MDR1. Once inside the cell, 
calcein-AM is irreversibly hydrolyzed to hydrophilic, intensively fluorescent calcein. 
Inhibition of MDR1 causes an increase of calcein-AM and calcein levels inside the cell 
(Figure 6). 
 
Figure 5. Vesicular transport assay. The amount of a substrate transported into the 
inside-out membrane vesicles is studied (SOLVO Biotechnology). 
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4.2.4 Utility of in vitro assays in studying MDR1-mediated interactions 
 
Szerémy et al. (2011) compared three assays (uptake, ATPase and vesicular transport 
assay) to study MDR1-mediated interactions using a common probe substrate calcein-
AM. The vesicular transport assay proved to be most sensitive to detect interactions 
with MDR1, even though calcein-AM is a highly permeable probe. The uptake assay 
showed the least sensibility, as for low permeability inhibitors no interaction was 
observed. This is likely due to inhibitors with low permeability not able to well 
permeate to binding site of MDR1 at the cytoplasmic leaflet. In the case of ATPase 
assay, Szeremy et al. suggested that more interactions would be detected, if both 
activation and inhibition modes are used instead activation mode alone. In the inhibition 
mode of the ATPase assay, inhibitors of the transporter inhibit the ATPase activity 
measured in the presence of s stimulating substrate. Also importantly, depending on the 
probe substrate, a drug may potentiate or inhibit MDR1-mediated transport due to 
allosteric interactions (Taub et al., 2005). In the study of Szeremy et al., Sf9-MDR1 
membrane vesicles were used for the ATPase assay and cells of human origin 
overexpressing MDR1 were used for the vesicular transport assay and different 
preparation methods were used. 
Figure 6. Uptake assay. Inhibition of MDR1 causes calcein-AM and calcein 
accumulation within the cell (modified from SOLVO Biotechnology). 
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Polli et al. (2001) compared three assays (MDCKII-MDR1 transport, uptake and 
ATPase) in identifying MDR1 substrates in drug discovery process. The transport assay 
showed tendency to fail with high permeability substrates, as the uptake (inhibition of 
calcein AM efflux) and ATPase assay tended to fail with low permeability substrates. 
Thus, compounds that cannot permeate well into the cell membrane, or the reconstituted 
lipid bilayer of a membrane vesicle in a concentration critical for the ATPase activation, 
may have a limited effect. Therefore the transport assay was chosen as a primary screen 
for MDR1 substrates. However, in the ATPase study membrane vesicles purified from 
insect cells (Sf9-MDR1) were used. Possibly the application of membrane vesicles 
purified from mammalian cells might improve the assay sensitivity. Keogh and Kunta 
(2006) validated a method using digoxin as a probe in a MDCKII-MDR1 transport 
assay. They suggested that the method is suitable for routine use to assess the in vitro 
inhibitory potency (IC50) of new drug candidates on MDR1-mediated digoxin transport. 
Comparison of IC50 values against clinical interaction profiles for the probe inhibitors 
indicated the in vitro assay would be predictive of MDR1-mediated clinical digoxin-
drug interactions mediated.  
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Assay type Tissues Parameters Applicability Limitations 
Cell based     
Transport Caco-2 
MDCKII-
MDR1 
LLP-PK1-
MDR1 
RB-A/A-B 
RMDR1/parental 
Km, Vmax 
IC50, Ki 
Evaluation of MDR1-
transport 
and inhibition. 
Directly measure efflux 
across cell barrier. 
Localization of 
transporters. 
 
Tends to fail to identify 
high permeability 
substrates. 
Uptake Tumor cells 
(e.g. 
vinblastine 
resistant Caco-
2, MDCKII-
MDR1) 
Accumulation of 
substrate in the presence 
and absence of MDR1 
activity. 
Inhibition of efflux of 
fluorescent probe (e.g. 
calcein-AM, rhodamine-
123). 
Primarily used for 
inhibition assay. 
Tends to fail to identify 
low permeability 
substrates and inhibitors. 
Accumulation assay 
cannot be used to 
differentiate substrate 
and inhibitors. 
Membrane 
based 
    
Vesicular 
transport 
Membrane 
vesicles (e.g. 
Sf9-MDR1, 
MDCKII-
MDR1) 
Km, Vmax 
IC50, Ki 
Evaluation of MDR1-
transport and inhibition. 
Effective model for 
kinetic studies. 
Tends to fail to identify 
high permeability 
substrates. 
ATPase  Membrane 
vesicles (e.g. 
Sf9-MDR1, 
MDCKII-
MDR1) 
ATPase stimulation Interaction with MDR1-
transporter 
Activation mode 
Inhibition mode 
Not a functional assay. 
Cannot be used to 
differentiate substrates 
and inhibitors. 
High intra- and 
interassay variability 
False negatives. 
 
4.3 In vitro inhibition parameters  
 
Ki and IC50 are commonly used to report the inhibitory capacity of drug compounds and 
to compare their relative inhibitory potency.  The inhibition constant, Ki, designates the 
equilibrium constant of the dissociation of the transporter-inhibitor complex. IC50 
determines the concentration of inhibitor needed to cause 50 % reduction in transport 
rate of another compound. In other words, smaller values for Ki indicate tighter binding 
and lower IC50 values suggest stronger inhibition. 
 
In general, IC50 is more commonly used to assess interactions. IC50 is determined at one 
concentration of a substrate over a scale of inhibitor concentrations. In order to calculate 
Ki, the rates of transport have to be determined by varying independently the 
Table 2. Utility of in vitro assays in studying MDR1-mediated interactions (adapted 
from FDA draft guideline, 2006)  
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concentrations of substrate and the concentration of inhibitor (Burlingham and 
Widlanski 2003). This is more labor- and time-consuming. IC50 value is dependent on 
the substrate and its concentration, whereas Ki is constant, depending only on the 
specific transporter and inhibitor. Because Ki does not depend on the substrate, it is 
more readily compared between different assays (experimental conditions) and 
laboratories to characterize inhibitors.  
 
If the mechanism of inhibition and the concentration of the substrate is known, an IC50 
value can be theoretically converted into Ki value using the equation of Cheng and 
Prusoff (1973) (Equation 2). According to this relationship the inhibitory potencies are 
related as a function of the concentration (S) and the Km value of the substrate. In the 
case of competitive inhibition, IC50 value approaches Ki when the assays are performed 
at substrate concentrations well below the Km value. Thus the IC50 value is always 
higher than Ki.  
 
           
 
  
  
 
Cer et al. (2009) developed a web-server tool for estimating Ki from experimentally 
determined IC50 values for inhibitors of enzyme activity and ligand binding. For enzyme 
kinetics, the tool uses classic Michael-Menten kinetics, which can be applied for 
transporter interactions as well. Required user-defined input values include the 
concentration and Km of the substrate and IC50 value. 
 
Mathematically most accurate way to determine IC50 value is by nonlinear regression. 
As an alternative way, Burlingham and Widlanski (2003) introduced a new analysis of 
the Dixon plot (Figure 8). Dixon plot is graphical method for determining Ki by 
assaying only two substrate concentrations against a range of inhibitors in the case of 
competitive inhibition (Dixon 1953) (Figure 7). Burlingham and Widlanski suggested 
that this linear method could be utilized to determine IC50 values as well, even if the 
mode of inhibition is unknown. 
 
Equation 2 
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IC50 values can be used to assess the relative inhibitory potencies of candidate 
compounds and classify them as weak or potent inhibitors. However, their utility is 
limited to predict the extent of drug-drug interactions. For quantitative predictions, in 
vitro kinetic parameters, Km and Ki are needed. 
 
4.4 In vivo methods for studying MDR1-interactions 
 
Mdr1 knockout mice have shown the significance of MDR1 transporter in 
pharmacokinetics of certain drugs. These results are utilized to develop in vitro - in vivo 
correlations to estimate the importance of MDR1 in the pharmacokinetics of substrate 
Figure 7. The Dixon plot for a competitive inhibitor. Ki can be determined from the 
intersection of data obtained at two substrate concentrations (Burlingham and Widlanski 
2003). 
.  
Figure 8. New analysis of the Dixon plot. The Dixon plot can be illustrated as a series of 
IC50 determinations (Burlingham and Widlanski 2003). IC50 approaches Ki, when the 
assay is performed at low concentration of substrate. 
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drugs. Using this information, the effect of an MDR1 inhibitor on a certain substrate 
could be estimated. Besides the substrate’s affinity to MDR1, the inhibitor’s inhibitory 
capacity contributes to the interaction. Inhibitory capacities are estimated in in vitro 
experiments, as in vivo parameters with varying concentrations of inhibitor would be 
extremely laborious and expensive to produce. However, the information from in situ 
and in vivo mice studies can be well exploited in interaction studies to predict the drugs 
susceptibility to an MDR1-mediated interaction. To perform an actual interaction study 
with predictive value in mice, concentrations of substrate and inhibitor would have to be 
in vivo relevant in human and then extrapolated to mice. 
 
4.5 Prediction of intestinal MDR1-mediated drug-drug interactions  
 
The latest FDA draft guidance (2006) for drug interaction studies presents the criteria 
for determining whether an investigational drug is a substrate (Figure 9) and/or an 
inhibitor (Figure 10) of MDR1 and whether an in vivo interaction study is needed. To 
evaluate if a drug is a substrate for MDR1, a bi-directional transport assay is 
recommended. If the net flux ratio is over 2, the result is considered positive and further 
studies with a known MDR1 inhibitor are should be performed. If the addition of a 
MDR1 inhibitor reduces the net flux ratio significantly (more than 50 % reduction), the 
drug is considered a likely MDR1 substrate. When an investigational drug is a MDR1 
substrate in vitro, available in vivo data should carefully evaluated to determine whether 
an in vivo drug interaction is needed. For example, the bioavailability of drugs that are 
classified as class I drugs according to the Biopharmaceutics Classificiation System 
(BCS), being highly soluble and highly permeable, may not be significantly affected by 
co-administration of a MDR1 inhibitor (Zhang et al, 2008).  
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To determine whether an investigational drug is an inhibitor of MDR1, a bi-directional 
transport assay using a probe substrate is recommended. The criteria states that the 
concentration of the probe should be below its apparent Km value. First, a high 
concentration (e.g. 100 µM or as high as the drug’s solubility allows) of the 
investigational drug can be used to see if the efflux of the probe is affected. If the efflux 
of the probe is inhibited by the investigational drug, the inhibition should be further 
studied over a range of concentrations to determine the inhibitory potency, IC50 or Ki. 
The next step is to calculate the ratio between the concentration of the drug (I) and the 
inhibitor potency (IC50 or Ki). If the ratio is over 0.1, the investigational drug is 
considered a MDR1 inhibitor and an in vivo drug interaction study with a MDR1 
substrate (generally digoxin) is recommended. 
 
Figure 9. Decision tree to determine whether a drug is a substrate for MDR1 and 
requires an in vivo drug interaction study (FDA draft guidance 2006; Giacomini 2010). 
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The FDA and EMEA draft guidances highly emphasizes the importance of a validated 
or sufficient cell system. To evaluate if an investigation drug is a MDR1 substrate, 
known probe substrate(s) should be used as a positive control(s). An acceptable cell 
system should produce net flux ratios of the probe(s) similar to what has been reported 
in the literature (a minimum net flux ratio of 2 is recommended). The same criteria 
apply to inhibition studies, and additionally two or three known potent MDR1 inhibitors 
should be included as positive controls.  
 
The difficulty in predicting intestinal drug-drug interactions is the estimation of the drug 
concentration in the intestine. In the draft guidance (2006) (I) represented the mean 
steady-state Cmax value for total drug (unbound and bound) following administration of 
the highest proposed clinical dose. This criteria further evolved leading to the proposal 
of alternative criteria: drugs that having a (I)1/IC50 ratio over 0.1 or (I)2/IC50 ratio over 
10 should be evaluated in an in vivo drug interaction study. (I)1 stands for the total 
plasma Cmax (unbound and bound) and (I)2 is obtained by dividing the dose by 250 ml, 
which is the typical amount of water taken with administration of a drug The 
concentration of drug in the intestine is taken into account also in the EMA draft 
guidance (2010) for permeability studies for investigational drugs. EMA states that 
permeability should be studied for at least four different physiologically relevant 
Figure 10. Decision tree to determine whether a drug is an inhibitor of MDR1and when 
an in vivo drug interaction study is recommended (Giacomini 2010)FDA draft guidance 
2006; (Zhang et al. 2008). 
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concentrations, which could be 0.1–50-fold the dose divided by 250 ml for intestinal 
transport. In comparison, when investigating systemic MDR1 transport the 
corresponding concentration range recommended is 0.1–50-fold the unbound Cmax. 
Importantly, because the methodology used for determination of the IC50 value greatly 
affects the ratio, there is a great need for standardization (Zhang et al., 2008). 
 
 
5 CONCLUSIONS 
 
It is of great importance that predictive information of potential MDR1-mediated 
absorption limitations and related drug-drug interactions is produced in early drug 
development. However, there’s lack of suitable in vitro and in vivo data (e.g. 
comparable parameters) for in vitro-in vivo correlations, predictive of the extent of 
MDR1 on drug absorption. In studying MDR1-mediated interactions, many in vitro 
assays are frequently applied, but there is a need for validated international in vitro 
protocols. For example, the IC50 values for inhibitors have marked differences between 
studies and laboratories. 
 
If a drug-drug interaction can be accurately explained in vitro, the in vivo influence in 
humans can be better predicted. In silico pharmacokinetic modeling has been widely 
utilized in predicting the influence of MDR1 on drug absorption. In the future, 
physiologically based pharmacokinetic modeling of drug-drug interactions with 
implemented kinetic parameters (Km, IC50, Ki) would greatly increase the value of both 
in vitro studies and in silico models. However, understanding of the mechanisms and 
assumptions involved is vital for interpreting drug interaction data and evaluating the 
risk of clinically significant interactions. 
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APPENDIX 1  
 ABBREVIATIONS FOR THE MODEL 
  
GE  Gastric emptying for solid drugs 
Kge  Gastric emptying rate constant for dissolved drug 
Kt  Transit rate constant (for solid and dissolved drug) 
Kd   Dissolution rate constant 
Ka  Absorption rate constant 
Peff  Effective permeability 
Kel  Elimination rate constant 
t ½  Half-life 
V lumen  Volume of liquid in lumen 
A enterocyte  Surface area of enterocyte 
V enterocyte  Volume of enterocyte 
Vd  Volume of distribution 
Km Substrate concentration, at which reaction rate is half of 
maximum 
Vmax  Maximum transport rate 
logD6.0  Partition coefficient at pH 6.0 
PSA  Polar surface area 
 
 
1 
 
1  INTRODUCTION  
 
Drug-drug interactions are a common problem during drug treatment and a cause of 
great number of hospital admissions within the EU (EMA 2010). Therefore, elucidation 
of transporter- and/or metabolic enzyme-mediated drug interactions is important part of 
early drug development. However, the knowledge about clinical consequences of 
transporter-mediated drug-drug interactions is still limited and more investigation is 
needed to improve our understanding (EMA 2010).  
 
MDR1 is the most extensively studied efflux transporter, widely expressed in many 
pharmacokinetic barriers in the body. Many inhibitors of MDR1 transporter are also 
inhibitors of CYP3A4 enzyme and it has been suggested that they act synergistically in 
the intestine to limit the bioavailability of orally administered drugs (Benet et al., 1996). 
However, the overlapping substrate specificity is commonly a confusing factor, when 
studying MDR1 inhibition. It complicates the extrapolation of in vitro data into in vivo 
situation and makes it more difficult to estimate the influence of each interaction 
separately. Thus, when studying MDR1 inhibition, the possible effect of CYP3A4 
inhibition has to be regarded, when interpreting the results. To fully understand to role 
of each, selective in vivo relevant inhibitors of each are needed. Because of the wide 
tissue distribution of MDR1, inhibition of the transporter may result in interactions due 
to a change in intestinal, renal, biliary or central nervous system efflux.  
 
There is an increased need to validate in vitro assays to produce information that is 
predictable against in vivo data. With the aid of in vitro techniques, substantial volumes 
of data can be produced effectively. If the observed clinically significant interactions 
can be accurately explained in vitro, better in silico models could be developed to 
predict the in vivo outcome in humans using the in vitro data. Possibly less laborious 
and costly preclinical animal data would be needed. Predictive models would be useful 
tools to guide clinical interaction studies and to estimate the clinical significance of a 
drug interaction in different situations and with different inhibitors. An important issue 
is the use of clinically relevant probes and inhibitors with clinically relevant 
concentrations in the in vitro assays. A MDR1-selective substrate that is suitable in in 
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vitro studies and in vivo trials in humans, would give a good basis for developing in 
vitro–in vivo predictive models. 
 
Aliskiren is the first orally active renin inhibitor, approved 2007 by the FDA for the 
treatment of primary hypertension. The renin–angiotensin-aldosterone system plays an 
important part in the physiological regulation of blood pressure. Excessive renin system 
activity may lead to hypertension and associated target organ damage (Weir and Dzau 
1999). Renin is the first, rate-limiting enzyme of the renin-angiotensin-aldosterone 
cascade, responsible for the conversion of angiotensinogen into angiotensin I. Aliskiren 
inhibits renin activity, with a great potency (IC50 = 0.06 nM (Wood et al. 2003)). 
Aliskiren is known as Tekturna® in the US and as Rasilez® in other markets, available 
in 150 mg and 300 mg tablets.  
 
Pharmacokinetics of aliskiren has been shown to be very sensitive to MDR1 inhibition 
in humans (Tapaninen et al. 2010a). Tapaninen et al. (2010) showed that MDR1- and 
CYP3A4-inhibitor itraconazole increased the mean Cmax of aliskiren 5.8-fold and its 
mean AUC0-∞ 6.5-fold in humans. However, itraconazole did not have a significant 
effect on the half-life of aliskiren. Tapaninen et al. suggested that this indicates an 
interaction during the first-pass phase in the small intestine. Because aliskiren 
undergoes only minor CYP -metabolism (aproximately 1.4 % of dose as oxidized 
metabolites (Waldmeier et al., 2007)) and has low hepatic extraction ratio (0.10 (Azizi 
et al., 2006)), inhibition of CYP3A4 in the liver during the first-pass phase cannot 
explain the interaction entirely.  
 
Aliskiren has been classified as a class III compound according to the Biopharmaceutics 
Classification System (BCS), having high solubility and low permeability (Table 1). 
Being an MDR1 substrate, aliskiren has a poor bioavailability of 2.6 % (Table 2). The 
absorbed dose of aliskiren was excreted mainly unchanged via the hepato-biliary route 
(91.9 % (Waldmeier et al., 2007)). Only 0.6 % of dose was recovered in the urine (0-
168 h) (Drugs@FDA), which suggests that renal interactions are unlikely. In vitro 
studies show, that aliskiren is not an inhibitor of MDR1 or CYP enzyme activity. 
Oxidation is catalyzed mainly by CYP3A4/5 enzymes. Aliskiren binds moderately to 
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plasma proteins (in vitro 49-52 %,), which contributes to a lower risk of interactions. 
Aliskiren displays linear pharmacokinetics based on AUC (0-96h) and Cmax in the dose 
range of 75 mg to 600 mg (Vaidyanathan et al. 2006). Aliskiren has moderate affinity 
for the human organic anion transporter (OATP2B1) (Km 72 µM) (Vaidyanathan et al. 
2008), which the hepatic uptake is thought to be mediated by.  
 
 
Physicochemical parameters for aliskiren Value Unit 
Aqueous solubility (pH 7.4) 
Molecular mass 
Molecular mass as hemifumarate salt 
logP (pH 7.4) 
pKa (as a free base) 
logD6.0
1 
PSA
1 
>350 
551.8 
609.8 
2.45 
9.49 
-0.28 
146.1 
mg/ml 
g/mol 
g/mol 
1 
Calculated by ACDLabs 
 
 
PK parameters for aliskiren Value 
Dose (mg) 
Tmax (h) 
Cmax (µM) 
AUC (µM×h) 
Apparent terminal t½ (p.o.) (h)
1 
Apparent terminal t½ (i.v.) (h)
2 
Absorption (% of dose) 
Bioavailability (%) 
CL (l/h)
2 
Vss (l)
2,3 
300 mg 
3 
0.46 
2.008 
48.7 
23.7 
≥ 3 
2.6 % 
9 
135 
1 
calculated between 48 and 144 hours after administration 
2
 calculated after i.v. administration 
3
(Azizi et al., 2006) 
 
In addition to being very sensitive to MDR1 inhibition in vivo (Tapaninen et al. 2010), 
aliskiren has a high affinity for the transporter in vitro (Km 2.1 µM in ATPase assay 
(Vaidyanathan et al. 2008)). Because aliskiren undergoes only minor metabolism, the 
influence of MDR1-mediated interaction alone can be better assessed. Aliskiren as a 
probe gives a good starting point for MDR1-mediated in vitro interaction studies.  
 
The interactions between aliskiren and MDR1 inhibitors itraconazole, ketoconazole and 
verapamil have not been studied in vitro. Tapaninen et al. (2010) suggested that the 
Table 1. Physicochemical parameters for aliskiren (Drugs@FDA)
Table 2. Pharmacokinetic parameters for aliskiren (Drugs@DFA).
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interaction between aliskiren and itraconazole in vivo was likely mostly due to 
itraconazole inhibiting MDR1 transport in the intestine, hence improving aliskiren 
absorption. Hydroxyitraconazole is itraconazole’s active metabolite. As an inhibitor of 
CYP3A enzyme (Von Moltke et al. 1998), hydroxyitraconazole may contribute to 
CYP3A-mediated interactions of itraconazole, whereas hydroxyitraconazole’s potential 
to inhibit MDR1 has not been investigated in vitro. In addition to itraconazole, 
ketoconazole and verapamil are well documented MDR1- and CYP3A4 inhibitors with 
differing inhibition profiles. It is of great interest to study if the MDR1-mediated 
interaction in vitro would be predictive of the extent of MDR1-mediated interaction in 
vivo. 
 
 
2 AIMS OF THE STUDY 
 
The objective of this experimental part was to study the MDR1-mediated transport of 
aliskiren and the related drug-drug interactions in vitro and in silico. Aims of the study 
were to (1) obtain Km and Vmax values for aliskiren by using the vesicular transport 
assay, (2) obtain IC50 values for ketoconazole, verapamil, itraconazole and 
hydroxyitraconazole and to calculate Ki values for itraconazole and hydroxyitraconazole, 
(3) assess the feasibility of MDCKII-MDR1 membrane vesicles in vesicular transport 
assay, (4) use a compartmental absorption and transit (CAT) model to simulate the 
intestinal absorption of aliskiren and related drug-drug interactions in vivo in humans by 
using the in vitro results.  
 
 
3 MATERIALS AND METHODS 
 
3.1 Drug compounds 
 
Aliskiren hemifumarate and ketoconazole were supplied by Toronto Research 
Chemicals Inc. (North York, Canada) and verapamil by Sigma-Aldrich (Germany). 
Itraconazole and hydroxyitraconazole were obtained from Jansen Research Foundation 
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(Titusville, New Jersey). Stock solutions were prepared in dimethyl sulfoxide (DMSO): 
aliskiren 5 mM, ketoconazole 25 mM, verapamil 100 mM, itraconazole 0.8 mM and 
hydoxyitraconazole 0.8 mM. In all experiments, stock solution or serial dilutions were 
added to the assay mix to produce a final DMSO concentration of 2 % of the total 
reaction volume (v/v). 
 
3.2 MDCKII-MDR1 cell culture 
 
Madin-Darby canine kidney II (MDCKII) renal epithelial cells expressing human 
MDR1 were originally received from Netherland Cancer Institute. The growth medium 
used was D-MEM (Gibco/BRL 61965-026), supplemented with 10% Fetal bovine 
Serum and 1 % Penicillin-Streptomycin solution (5000 U/ml – 5 mg/ml, Gibco). 
MDCKII-MDR1 cells were split twice a week after a confluent monolayer was formed. 
Cells were first washed briefly with DPBS, incubated with 0.25 % trypsin/EDTA for 3-
5 minutes at 37 °C and then split 1:10. 
 
MDCKII-MDR1 cell mass was collected for the preparation of membrane vesicles. At 
the time of collection, cells had been split over 4 times and been grown for less than 
three months. Cells were kept on ice and detached from the tissue culture flask to cold 
PBS with a cell scraper. After 5 min centrifugation (+ 4 °C, 1000 g) the supernatant was 
removed. Cell mass was frozen in liquid nitrogen and stored in the freezer -75 °C until 
use. 
 
3.3 Sf9-MDR1 and Sf9-β-galactosidase cells 
 
Sf9 (Spodoptera frugiperda) insect cells expressing human MDR1 or β-galactosidase 
(control) were used to prepare membrane vesicles. Sf9 cells had been infected with a 
recombinant baculovirus containing the cloned MDR1 gene. Sf9 cells expressing β-gal 
were produced in similar manner, but the foreign gene in the baculovirus is a gene 
coding β-gal instead of MDR1. 
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3.4 Preparation of membrane vesicles 
 
Inside-out membrane vesicles were prepared mainly as described in (Chu 2004). 
Preparation of membrane vesicles was done on ice and using ice-cold buffers. Cells 
were washed twice with harvest buffer containing 50 mM Tris-HCl (pH 7.0) and 300 
mM mannitol and centrifuged (Centurion) + 4 °C, 800 g, 5 min. Cells were lysed and 
homogenized in membrane buffer containing 50 mM Tris-HCl (pH 7.0), 50 mM 
mannitol and 2 mM EGTA, using Dounce homogenizator (Pestle B), for 40 strokes. 
Cell lysates were centrifuged + 4 °C, 800 g, 10 min to separate the nuclei. The 
supernatant was further ultracentrifuged (Beckman Coultier, Optima LE-80K; rotor 50.2 
Ti, 91E733) + 4 °C, 100 000 g, 1 h 15 min to separate the cell membranes. The pellet 
containing the membranes, was resuspended in membrane buffer by pushing through a 
27G needle for 20 times to form inside-out membrane vesicles. Membrane vesicles 
were frozen in liquid nitrogen and stored in the freezer- 75°C until use. Same 
preparation method was used for both mammalian (MDCKII-MDR1) and insect cells 
(Sf9-MDR1). 
 
3.5 Determination of the protein concentration of membrane vesicles 
 
The protein concentration of membrane vesicles was determined by the Bio-Rad Protein 
Assay (Standard Procedure for Microtiter Plates). Standards were diluted in membrane 
buffer from 5 mg/ml bovine serum albumin stock solution, for the range of 0.05 to 1 
mg/ml. Absorbance was measured at 595 nm by Varioskan (Flash, Thermo Scientific).  
 
3.6 ATPase assay 
 
ATPase assay was used to measure the effect of aliskiren on the ATPase activity of 
human MDR1 expressed in Sf9 insect cell membrane vesicles. In the assay, transport 
activity of MDR1 is determined by the amount of inorganic phosphate (Pi) that is 
liberated according to the hydrolysis of ATP to ADP (Sarkadi 1992). Thus, the amount 
of Pi liberated is proportional to the activity of that transporter, which substrates of the 
transporters stimulate. Liberated Pi is detected by colorimetric reaction.  
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A 0.5 mg/ml membrane suspension was made in an assay mix and distributed onto the 
96 well plate on ice. Serial dilutions of aliskiren and verapamil (control drug), were 
added to the well plate in 1 µl DMSO. 60 mM NA3VO4 was added to the designated 
wells. The plate was preincubated at 37 °C for 5 min and the ATPase reaction was 
started by the addition of 25 mM Mg-ATP. After 20 min incubation at 37 °C, the 
reaction was stopped by adding sodium dodecyl sulfate (SDS 5%). The plate was 
incubated with the freshly prepared colorimetric detection reagent (35 mM ammonium 
molybdate in 15 mM zinc acetate and 10 % ascorbic acid) at 37 °C for 25 min. 
Absorbance was measured at 655 nm by Varioskan and amount of free phosphate (Pi) 
liberated (nmol/well) was calculated using the phosphate standard curve.  Na-
orthovanadate (Na3VO4) is a specific inhibitor for the ABC transporters (Urbatch et al., 
1995). Na3VO4–sensitive ATPase activity was calculated as the amount of Pi liberated 
per milligram membrane protein per minute (nmol/mg/min), substracting the values 
obtained in the presence of Na3VO4 from the values obtained in the absence of Na3VO4.   
 
3.7 Vesicular transport assay 
 
In the case of inside-out membrane vesicles, efflux proteins transport the substrates 
from the buffer into the membrane vesicles in the presence of ATP. The quantity of the 
transported substrate can then be measured. In this assay, the amount of aliskiren (nmol) 
transported into the Sf9-MDR1 membrane vesicles was measured. ATP-dependent 
transport of aliskiren (nmol/mg/min) was further calculated.  
 
3.7.1 Determination of test circumstances 
 
Determination of linearity of transport as function of time and optimization of protein 
amount (µg) in reaction were carried out. Aliskiren was assayed in the concentration 
range of 1, 10 and 100 µM with incubation times 1, 3, 10, 15 and 30 min. Protein 
amount of 50 µg was used. Aliskiren concentration 10 µM was further assayed with 
protein amounts 20 and 50 µg for incubation times 1, 3, 15 min and with protein 
amounts 20, 50 and 100 µg for the 10 min incubation time. 1 min incubation time 
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showed the highest rate of ATP-dependent transport (nmol/mg/min) in both assays and 
was therefore used as reaction time for the further experiments. No saturation of 
transport was observed between different protein amounts in the reaction. Protein 
amount of 50 µg was selected, because the experience was that it shows less variation 
than the smaller protein amount of 20 µg.  
 
3.7.2 Determination of Km and Vmax for aliskiren 
 
Aliskiren concentrations 0.5, 1, 2, 4, 8, 10, 16 and 32 µM were used for the 
determination of Km and Vmax values. A mix of membrane suspension and aliskiren 
dilution in DMSO was made to assay mix and distributed to the desired wells. 
Verapamil (100 µM) in 0.75 µl DMSO was used as a control. The plate was pre-
incubated at 37 °C for 15 min and reaction started by addition of preincubated Mg-ATP 
or assay mix. The plate was incubated at 37 °C for 1 min and reaction stopped by 
adding ice-cold washing mix. The samples were transferred to a 96 well filter plate 
(MultiScreen, Millipore, Ireland) and rinsed 5 times with washing mix. After the filters 
had dried, 100 µl 0.1 M ammoniumhydroxide was added to each well and incubated in 
room temperature for 10 minutes. The samples were then transferred through the filter 
to a 96 well plate by suction.  
 
3.7.3 Determination of IC50 and Ki for inhibitors 
 
Aliskiren concentration of 2 µM was used for the determination of IC50 values for 
inhibitors. For ketoconazole and verapamil, concentrations of 0.1, 1, 2, 4, 8, 16, 32 and 
100 µM were used. For itraconazole, the concentrations were 0.1, 0.25, 0.5, 1, 2, 4, 6 
µM and for hydroxyitraconazole 0.1, 0.25, 0.5, 1, 2, 4, 6 and 8 µM. The solubility of 
itraconazole and hydroxyitraconazole in 800 µM stock solution in DMSO and in assay 
mix in the concentrations used, was ensured with nephelometer (Nepheloskan Ascent, 
Labsystems, Finland). To determine the Ki for itraconazole and hydroxyitraconazole, 
aliskiren concentrations of 1, 2 and 8 µM were used against the range of inhibitor 
concentrations.  
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In ketoconazole and verapamil vesicular transport assays, the volume of inhibitor added 
to the wells, was increased to improve pipeting accuracy. Inhibitor dilution in DMSO 
was mixed with assay mix and 5.75 µl of the inhibitor solution was added instead of 
0.75µl. To start the reaction, 20 µl of ATP-Mg or assay mix was added instead of 25 µl, 
so that the volume of reaction and DMSO concentration of 2 % remained the same. 
Accordingly, ATP-Mg dilution was made stronger, so that the amount of ATP in the 
reaction was sufficient. 
 
3.8 Measuring of aliskiren 
 
Aliskiren samples were measured using UPLC-MS/MS technique. ULPC (Acquity, 
Waters, USA) column used was UPLC HSS T3 with dimension 2.1 x 100 mm and 
particle size 1.8 µm (Waters, USA). Flow rate was 0.3 ml/min and injection volume 10 
µl. Mobile phase A was 0.1 % formic acid and mobile phase B acetonitrile.  Mass 
spectrometry used was TandemQuadrupole, model G6410A (Agilent, USA). 
Propranolol was used as an internal standard.  
 
3.9 Sigma plot 
 
Km and Vmax values for aliskiren and IC50 values for inhibitors were calculated from the 
in vitro results by SigmaPlot (Systat Software Inc, USA) using nonlinear regression 
analysis. One site saturation equation was used to obtain Km and Vmax and one site 
competition equation for IC50 values. Weighing did not improve the fittings, thus none 
was used. For itraconazole and its metabolite, Ki was calculated (Equation 1) using three 
IC50 values obtained by using three different aliskiren concentrations (1, 2 and 8 µM). 
 
   
    
   
 
   
 
 
 
 
Equation 1 
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3.10 Pharmacokinetic modeling 
 
Model was constructed using Stella ™ modeling software (isee systems version 9.0.1, 
USA). Compartmental absorption and transit (CAT) model (Yu et al., 1996) was used 
as a basis, to which an enterocyte compartment and MDR1-mediated efflux was added 
(Figure 1). Passive permeation on the apical and basolaterial membrane of the 
enterocyte was represented with the following equation (Equation 2): The model 
parameters are presented (Table 3). 
 
 
                    
 
 
 
 
 
 
 
Equation 2
Figure 1. Pharmacokinetic model for simulating intestinal absorption of MDR1 
substrates and the effect of MDR1 inhibition (modified from (Kortejärvi et al., 2007) 
and material from V-P Ranta). 
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Model parameters.  
Model parameter Value Unit Reference 
GE 4250 µg/min Kortejärvi et al., 2007 
Kge 0.0583 min
-1
 Kortejärvi et al., 2007 
Kt 0.035 min
-1
 Yu et al., 1996 
Kd 0.0317 min
-1
 Yu et al., 1996 
Ka 6.01 x 10
-3
 min
-1
 Linnankoski et al.,2006 
Peff
 
0.00451 cm/min   
Kel 4.87 x 10
-4
 min
-1
   
t ½ 23.7 h
-1
   
V lumen 35.7 ml   
A enterocyte 2857 cm
2
   
V enterocyte 2.86 cm
3 
(ml)   
Vd 135000 ml Azizi et al., 2006 
Hepatic extraction 
ratio 
0.10   Azizi et al., 2006 
Km 2.79 µg/ml   
Vmax
1
 1.6 x 10
-4 
 µg/cm
2
/min Vaidyanathan et al., 2008 
Vmax
2
 0.0861 µg/cm
2
/min Tang et al., 2002 
logD6.0  -0.28   Calculated by ACDLabs 
PSA  146   Calculated by ACDLabs 
 
 
4 RESULTS  
 
4.1 ATPase assay 
 
Aliskiren increased liberated inorganic phosphate (Pi) (nmol/mg/min) in Sf9-MDR1 
membranes, suggesting enhanced activity of MDR1 transporter (Figure 2). However, 
the results showed great variation (n = 6). At the highest, aliskiren increased liberated Pi 
52 % (at 5 µM concentration), which is proportional to the enhanced activity of the 
Table 3.  
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transporter. Verapamil was used as a positive control, known to stimulate the baseline 
ATPase activity of MDR1 transporter. Verapamil increased liberated Pi 85 % at the 
highest (at 10 µM concentration), indicating stronger activation of the transporter than 
aliskiren (Figure 3). 
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Figure 2. Na3VO4-sensitive ATPase activity of Sf9-MDR1 membranes in the presence 
of aliskiren. Aliskiren increased liberated Pi (nmol/mg/min) (mean ± SD), suggesting 
enhanced activity of MDR1 transporter (n = 6).  
Figure 3. Na3VO4-sensitive ATPase activity of Sf9-MDR1 membranes in the presence 
of verapamil. Verapamil was used as a positive control, known to increase liberated Pi 
(nmol/mg/min) (mean ± SD) in MDR1 membranes (n = 6). 
13 
 
 
4.2 Vesicular transport assay 
 
4.2.1 Feasibility of MDCKII-MDR1 membrane vesicles 
 
ATP–dependent transport of aliskiren was concentration dependent (Figure 4, Figure 5). 
Shape of the figure (3 concentrations used: 1, 10 and 100 µM) is very similar in both 
MDCKII and Sf9 membranes, only MDCKII membranes gave lower values for the 
ATP-dependent transport (nmol/mg/min). Vesicular transport study with MDCKII-
MDR1 membranes was performed only once, thus requires additional experiments. 
Furthermore, incubation time of 15 min was used, which was later reduced to 1 min 
because of saturation after.    
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Figure 4. ATP-dependent transport of aliskiren in Sf9-MDR1 membranes (n = 1). 
Incubation time of 15 min was used.  
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4.2.2 Determination of test circumstances 
 
The rate of ATP-dependent transport of aliskiren was highest with incubation time of 1 
min, and showed saturability after (Figure 6, Figure 7).  Protein amounts 20, 50, 100 µg 
in the reaction showed no difference in the rate of ATP-dependent transport (Figure 7), 
suggesting that the transport is not saturated due to limited amount of transporter in the 
reaction. In the latter study, comparing the circumstances of incubation time 1 min and 
protein amount 50 µg, the rate of ATP-dependent transport was higher.  
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Figure 5.  ATP-dependent transport of aliskiren in MDCKII-MDR1 membranes (n = 1). 
Incubation time of 15 min was used. 
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4.2.3 Determination of Km and Vmax for aliskiren 
 
ATP-dependent transport of aliskiren showed saturable kinetics with Km of 5.05 µM and 
Vmax of 0.89 (nmol/mg/min) (Figure 8, Table 4).  
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Figure 6. Incubation time 1 min showed the highest rate of ATP-dependent transport of 
aliskiren (nmol/mg/min). Aliskiren concentration 10 µM and protein amount 50 µg 
were used.  
Figure 7. No saturation of ATP-dependent transport of aliskiren was observed with 
varying protein amounts 20, 50 and 100 µg in the reaction. Aliskiren concentration 10 
µM and incubation times 1, 3, 10 and 15 min were used. 
16 
 
 
 
Km and Vmax values for aliskiren calculated with SigmaPlot (n = 3). 
Coefficient Value SD Unit 
Km 5.1 3.5 µM 
Vmax 0.89 0.13 nmol/mg/min 
 
4.2.4 Determination of IC50 and Ki for inhibitors 
 
Itraconazole (Figure 11) and hydroxyitraconazole (Figure 12) inhibited MDR1-
mediated transport of aliskiren (2 µM) in Sf9-MDR1 membranes with an IC50 of 1.7 
and 1.0 µM, respectively (Table 5). Ketoconazole (Figure 9) and verapamil (Figure 10) 
were less potent MDR1 inhibitors with IC50 values of 15.7 and 18.2 µM (Table 5). Ki 
calculated for itraconazole was 0.82 and for hydroxyitraconazole 0.61 (Table 5). ATP-
dependent transport of different concentrations (1, 2 and 8 µM) of aliskiren in the 
presence of itraconazole, predicted by SigmaPlot, is presented (Table 13). 
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Figure 8. ATP-dependent transport of aliskiren (mean ± SD) in Sf9-MDR1 membranes 
(n = 3). 
Table 4.  
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Figure 10. ATP-dependent transport of 2 µM aliskiren (mean ± SD) in Sf9-MDR1 
membranes in the presence of verapamil. Verapamil concentrations of 0.1, 1, 2, 4, 8, 16, 
32 and 100 µM were used to determine the IC50 value (n=3). 
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Figure 9. ATP-dependent transport of 2 µM aliskiren (mean ± SD) in Sf9-MDR1 
membranes in the presence of ketoconazole. Ketoconazole concentrations of 0.1, 1, 2, 4, 
8, 16, 32 and 100 µM were used to determine the IC50 value (n = 3). 
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Figure 11. ATP-dependent transport of 2 µM aliskiren (mean ± SD) in Sf9-MDR1 
membranes in the presence of itraconazole. Itraconazole concentrations of 0.1, 0.25, 0.5, 
1, 2, 4 and 6 µM were used to determine the IC50 and Ki values (n = 3). 
Figure 12. ATP-dependent transport of 2 µM aliskiren (mean ± SD) in Sf9-MDR1 
membranes in the presence of hydroxyitraconazole. Hydroxyitraconazole 
concentrations of 0.1, 0.25, 0.5, 1, 2, 4 and 8 µM were used to determine the IC50 and Ki 
values (n = 3). 
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 IC50 (µM) STD Ki STD 
Ketoconazole 15.7 4.8   
Verapamil 18.2 4.9   
Itraconazole 1.7 0.2 0.82 0.46 
Hydroxyitraconazole 1.0 0.3 0.61 0.32 
 
4.2.5 Pharmacokinetic modeling 
 
In the model, in order to correctly simulate reported plasma Cmax 254 ng/ml for aliskiren 
(Drugs@FDA) using the experimental Km value (2.89 µg/ml), in vivo relevant value for 
Vmax could not be used (Table 6). Instead, Vmax had to be increased roughly 100-fold 
(50000 µg/min), suggesting that the drug concentration in enterocytes did not reflect the 
in vitro or in vivo situation.   
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Figure 13. ATP-dependent transport of three concentrations of aliskiren (1, 2 and 8 µM) 
in Sf9-MDR1 membranes in the presence of itraconazole, predicted by SigmaPlot. 
Table 5. IC50 values for the inhibitors calculated by SigmaPlot (aliskiren concentration 
of 2 µM). Ki values were calculated from IC50 values obtained by using three different 
aliskiren concentrations (1, 2 and 8 µM). 
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To increase the drug concentration in enterocytes, thus to enhance the active efflux by 
MDR1 in the model, the passive permeability of aliskiren in the basolateral membrane 
was decreased. The basolateral surface area (basol. A) was decreased to 1/10 and 1/100. 
In the same circumstances (same values for Km and Vmax), the reduction of basolateral 
surface area resulted in smaller plasma Cmax (Table 6), suggesting a better description 
for the passive permeability of drug in the basolateral membrane.   
 
Table 6.  Simulated mean plasma Cmax values for aliskiren. 
Predicted Cmax (ng/ml) Ba (%) Basol. A Km (µg/ml) Vmax (µg/min) 
20 mg i.v. 140     
300 mg p.o. 240 11 1 2.79 50000 
300 mg p.o. 1810 11 1 2.79 500 
300 mg p.o. 120 6 1/10 2.79 50000 
300 mg p.o. 20 1 1/100 2.79 50000 
300 mg p.o.  without MDR1 1880 84 1   
 1880 84 1/10   
 1240 55 1/100   
Experimental in vivo      
300 mg p.o.
1 
240 3    
150 mg p.o. after 
itraconazole
 
treatment
2 
766     
1
Drugs@FDA 
2
Tapaninen et al. 2010a 
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5 DISCUSSION  
 
5.1 Correlations of in vitro parameters to in vivo literature data 
 
5.1.1 Aliskiren  
 
Aliskiren showed concentration-dependent transport and high affinity for MDR1 with a 
Km value 5.1 µM (± 3.5). Km calculated for aliskiren was quite close to the earlier data 
of 2.1 µM (± 0.5) obtained from an ATPase assay using Sf9-MDR1 membranes and 3 
µM obtained in a Caco-2 transport assay (Vaidyanathan et al. 2008). ATPase assay is 
generally not recommended for kinetic studies, because it is not a functional assay 
measuring the actual transport of a substrate. However, the results obtained from the 
three different assay systems are consistent. Calculation of the Km for aliskiren served as 
a validation of the method. The use of another known probe substrate (e.g. digoxin) to 
compare to literature would have improved the credibility of the study more.  
 
The mean plasma Cmax of aliskiren after a 300 mg dose was 0.46 µM (Drugs@DFA), 
which is below the in vitro Km value of aliskiren. This suggests that systemic saturation 
of MDR1 transport is unlikely, but due to great inter-individual variability in 
pharmacokinetics of aliskiren, this option cannot be ruled out entirely. In the intestine, 
the concentration of the drug is evidently higher. EMA draft guidance (2010) 
recommends that in studying intestinal transport, the drug could be studied over the 
concentration range 0.1 – 50-fold the dose divided by 250 ml, which is the typical 
amount of water a drug is swallowed with. For aliskiren, theoretically 300 mg / 250 ml 
would result in an intestinal concentration of 2.17 mM, 1000-fold the Km value. 
However, the concentration of drug in the binding site of MDR1 ((the cytosolic leaflet 
of lipid bilayer (Shapiro and Ling 1997)) is the concentration that determines the active 
efflux transport by MDR1. In vivo, aliskiren has been shown to display linear 
pharmacokinetics (AUC (0-96h) and Cmax) in a dose range of 75 mg to 600 mg 
(Vaidyanathan et al. 2006). 
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The maximum rate of transport (Vmax) depends on the expression of MDR1, which is 
not likely as high in vivo in the human intestine as in Sf9-MDR1 cell line. Perhaps the 
Vmax value could be utilized to compare the expression of MDR1 in different cell lines. 
Also, similar Vmax value throughout the experiments gives confirmation, that the 
expression of MDR1 is same, when different passages of cell lines or different batches 
of membrane vesicles are used.  
 
5.1.2 Inhibitors 
 
IC50 value for inhibitor depends on the substrate, substrate concentration, assay system 
and cell line used. Thus, comparing the inhibitory potencies of different inhibitors 
obtained in different studies and laboratories is challenging (Table 7). However, the 
IC50 values obtained for ketoconazole and verapamil in this in vitro study suggest 
weaker inhibition of the MDR1-mediated transport than what has been reported 
previously (Table 7). The IC50 values do seem to correlate quite well to the in vivo 
clinical interaction studies with aliskiren (Table 8). 
 
Table 7.IC50 values obtained in this in vitro study and previously reported in the 
literature.  
 Experimental Literature    
Cell line Sf9-MDR1 Sf9-MDR1
1 
Caco-2
2 NIH-3T3-
G185
3 
MDCKII-
MDR1
4 
Ketoconazole 
Verapamil 
Itraconazole 
Hydroxyitraconazole 
Cyclosporine A 
15.7 
18.2 
1.7 
1 
 
2.2 
5.2 
1.2 
2.1 
 
 
1.3 
5.6 
 
1.7 
 
1.4 
3.7 
5.9 
1.3 
1
Obtained in vesicular transport study with calcein AM as substrate (Szeremy et al., 2011). 
2
Obtained in transport study with digoxin as substrate (FDA 2006). 
3
Obtained in uptake study with fluorescent daunorubicin as substrate (NIH-3T3-G186 cell line contains 
human MDR1) (Wang et al., 2001).  
4
Obtained in transport study with digoxin as substrate (Keogh and Kunta 2006) 
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Table 8. Comparison of MDR1-mediated interactions with aliskiren in vitro to in vivo 
clinical interaction studies. For IC50 determination aliskiren concentration of 2 µM was 
used.  
 In vitro  In vivo  
 IC50 (µM) Ki AUC Cmax 
Ketoconazole 15.7  2-fold
1 
2-fold
1 
Verapamil 18.2  1.8-fold
2 
1.8-fold
2 
Itraconazole 1.7 0.82 6.5-fold
3 
5.8-fold
3 
Hydroxyitraconazole 1.0 0.61   
1 
Vaidyanathan et al., 2008 
2 
Rebello et al., 2010 
3 
Tapaninen et al., 2010 
 
Quinney et al. (2008) showed in an in vivo rat study, that the active metabolite of 
itraconazole, hydroxyitraconazole, is formed during the intestinal first pass metabolism 
by CYP3A4. The result was consistent with earlier studies. In addition, compared to 
itraconazole the systemic concentrations of hydroxyitraconazole were higher and 
declined more slowly. In our study, hydroxyitraconazole was shown to be a potent 
MDR1 inhibitor in vitro with similar inhibitor potency to itraconazole (or even more 
potent). This suggests that the metabolite has potentially a highly significant 
contribution to the MDR1-mediated interactions with itraconazole.  
 
Itraconazole and ketoconazole have both been regarded as potent inhibitors of MDR1 
(Table 7) and CYP3A4 in vitro (IC50 values 0.12 and 0.012 µM respectively (Wang et 
al., 1999)). Thus, ketoconazole is even 10 times more potent CYP3A4 inhibitor in vitro 
than itraconazole. Hydroxyitraconazole inhibited CYP3A4 with an IC50 value of 0.23 
µM (Wang et al., 1999). In vivo in humans, itraconazole and ketoconazole both 
increased midazolam (substrate for CYP3A4 but not MDR1) AUC0-∞ 10-fold and 15-
fold respectively (Olkkola et al., 1994), which correlates to ketoconazole being more 
potent CYP3A4 inhibitor.  
 
However the in vivo interaction between ketoconazole and aliskiren was not as 
significant as the interaction between itraconazole and aliskiren. Ketoconazole increased 
aliskiren Cmax and AUC approximately 1.8-fold in humans (Vaidyanathan et al. 2008). 
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Interaction was not associated with safety or tolerability issues and no dose adjustments 
were recommended with co-administration.  This suggests that ketoconazole might not 
be as potent inhibitor of MDR1 as itraconazole, which the results from our in vitro 
interaction studies support (Table 8). Interaction between itraconazole and aliskiren is 
probably of clinical importance and simultaneous use should be avoided (Tapaninen et 
al., 2010a). A 6-fold increase in aliskiren exposure might increase the risk of 
hypotension and adverse effects, especially in continuous treatment in patient 
population. Also, possible inter-individual variation in the extent of interaction has to be 
considered, as aliskiren has showed notable interindividual variability even in the group 
of healthy subjects.  
 
Verapamil has been regarded as only a moderate inhibitor of MDR1 (Table 7) and a 
weak inhibitor of CYP3A4 in vitro (IC50 value 23 µM (Wang et al., 1999)). In vivo in 
humans, verapamil increased aliskiren Cmax and AUC approximately 2-fold (Rebello et 
al., 2010). Such level of aliskiren exposure was safe and well tolerated in healthy 
participants and no dose adjustments were needed. In vivo interactions of ketoconazole 
and verapamil with aliskiren seem to be of similar class, as were the IC50 values 
obtained in our study.  The results suggest that ketoconazole and verapamil both are 
moderate inhibitors of MDR1. In vivo verapamil increased midazolam AUC0-∞ 3-fold 
(Backman et al., 1994), a lot less than potent the CYP3A4 inhibitors ketoconazole and 
itraconazole. This correlates to the in vitro evaluation of verapamil being a weak 
CYP3A4 inhibitor. In further studies, it would be interesting to obtain Ki values for also 
ketoconazole and verapamil.  
 
Another interesting MDR1 inhibitor to study in vitro in further studies is cyclosporine. 
Cyclosporine is also a potent inhibitor of MDR1 (Table 7) and a weak inhibitor of 
CYP3A4 (IC50 <50 µM, (FDA draft guidance 2006)). Coadministrated with aliskiren, 
cyclosporine increased aliskiren Cmax 2.5-fold and AUC 4-5-fold (Rebello et al., 2011). 
It would be interesting to compare IC50 and Ki values for cyclosporine to itraconazole’s, 
as the extent of the in vivo interaction was not quite as pronounced as with itraconazole. 
But, it has to be considered that the clinical trial arrangements in studying these 
interactions differed. In the itraconazole interaction study, aliskiren (150 mg) was given 
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on a day 3 of a 5-day treatment with itraconazole, whereas in the cyclosporine 
interaction study aliskiren (75 mg) was given simultaneously with cyclosporine. 
Perhaps the interaction appears more pronounced, when the inhibitor is given first and 
the binding sites of MDR1 are already occupied. Another explanation for the stronger in 
vivo interaction with itraconazole could be the contribution of its metabolite. 
Itraconazole and its metabolite are both also potent CYP3A4 inhibitors, which may 
enhance the intestinal availability of aliskiren.  
 
5.1.3 Limitations of in vitro assays applied 
 
We used the ATPase assay to confirm the interaction between aliskiren and MDR1 
transporter. ATPase assay can be used as a screening tool to identify substrates of 
MDR1, but it is not designed to distinguish substrates from inhibitors. As was observed 
in our studies, ATPase assay showed high intra- and inter-assay variability. To avoid 
false negatives, substrates have to be assayed in wide enough range of concentrations, 
because different concentrations can stimulate the ATPase activity a different amount. 
In order to do this, the substrate has to be soluble enough. Another complication was the 
assay yielding a high value (liberated Pi) for the pure solvent (DMSO), as also DMSO 
stimulates the ATPase activity.   
 
In vesicular transport assay, the transporter is located on the outer membrane of the 
inside-out membrane vesicle, being more available for the substrate. For drugs with 
poor permeability (e.g. aliskiren) this enhances the access to the transporter. On the 
other hand, for drugs with high permeability the effect of active transport can go 
unnoticed as the passive permeability and active transport occur to the same direction in 
this assay. Therefore the vesicular transport assay does not suite as well for identifying 
high permeability MDR1-substrates. However, because the MDR1 efflux is more 
relevant for low permeability drugs, this limitation does not pose a problem. Verapamil 
(100 µM) was used as a method control. Verapamil inhibited the transport of 2 µM 
aliskiren so that the amount of aliskiren (nmol) recovered inside the membrane vesicles 
was the same as was passively diffused, without ATP involved. Vesicular transport 
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assay should be an effective model for kinetic studies and was shown a sensitive 
method to detect MDR1-mediated drug-drug interactions (Serezemy et al., 2010). 
 
The results obtained are preliminary. More repeated experiments and standardization of 
the test circumstances are needed to improve presicion and repeatability. Sources of 
variation could have been the use of different batches of membrane vesicles and/or 
differences in the protein measurement. Aliskiren was measured by UPLC/MS-MS and 
propranolol was used as an internal standard. Propranolol is not an ideal internal 
standard for aliskiren, but gave accurate enough results for our experiments. An 
important limitation in our study, and in vitro studies in general, was the poor water 
solubility of itraconazole and its metabolite. For itraconazole and hydroxyitraconazole 
only concentrations up to 6 and 8 µM respectively could be used in the assays. Poor 
solubility of drugs can prevent comprehensive in vitro interaction studies.  
 
Use of MDCKII-MDR1 membrane vesicles in the experiments turned out to be 
laborious and costly. A large amount of cells was needed to be grown in order to purify 
enough membrane vesicles for only one experiment. The same membrane vesicle 
preparation method was used for both MDCKII and Sf9 cells. The preparation method 
used was originally for Sf9-MRP2 cells. Thus, more investigation is needed to see if the 
method can be optimized for MDR1 expressing cells and mammalian cells. It would 
give us more insight, if the amount of inside-out membrane vesicles (%) was 
determined. The expression level of MDR1 and the composition of the cell membrane 
can differ in insect and mammalian cells. Addition of cholesterol to Sf9 membranes has 
been attempted to mimic the mammalian membrane and to improve the in vivo 
relevance of the assays. 
 
5.2 Pharmacokinetic modeling  
 
5.2.1 Discussion  
 
Due to time limitations, only a simple pharmacokinetic model was tested to see the 
possibility for further development. The intestinal absorption of aliskiren was simulated 
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with and without the effect of active efflux by MDR1 and the resulting plasma 
concentrations (Cmax) were compared to reported aliskiren plasma concentrations in vivo. 
The resulting aliskiren plasma concentrations from simulations without MDR1 efflux 
were compared to in vivo situation with a potent MDR1 inhibitor. 
 
Aliskiren has poor oral bioavailability of approximately 3 % (Drugs@FDA). After a 
single dose of 300 mg, aliskiren average Cmax of 254 ng/ml was reported. However great 
inter-individual variability has been observed (e.g. 215 ± 122 ng/ml (n=19); 
(Vaidyanathan et al. 2006)). After 20 mg i.v. dose, the simulated Cmax was 140 ng/ml 
(dose/Vd) (Table 6). With the assumed Vd in the model, bioavailability of 3 % after 300 
mg dose would result in Cmax of only 70 ng/ml, suggesting that the Vd used in the model 
may be incorrect. Aliskiren does display multicompartmental kinetics (Vaidyanathan et 
al., 2008), which has not been taken into account in the model. Comparison could not be 
made to AUC values from literature, as the simulated values were higher. 
 
The model failed to demonstrate the plasma Cmax observed in vivo by using the 
experimental Km value and in vivo relevant value for Vmax.  The problem in the model 
seemed to be too rapid permeation through the enterocyte resulting in low intracellular 
aliskiren concentration. Permeation was described with the equation: 2 x Peff x A x (Cd – 
Cr) on both apical and basolateral membranes. In the basolateral permeation, 
concentration of aliskiren in blood (Cr) was assumed 0, because of sink conditions.  
 
To describe MDR1 activity in the human intestine in vivo, Vmax values obtained for 
vinblastine and aliskiren in Caco-2 transport assays (0.0861 and 0.00016 µg/cm
2
/min 
respectively) were used as rough estimates. Simcyp® pharmacokinetic modeling 
software uses a scaling factor 2.04 for scaling Caco-2 cell line to human intestine 
(jejunum), based on the ratio of total MDR1 to total protein in vitro and in vivo. Using 
the higher value for Vmax (0.0861 nmol/cm
2
/min) and an estimate for enterocyte 
compartment membrane surface area (A) 2857 cm
2
, value 246 µg/min for Vmax is 
calculated. Scaling of this to human intestine (jejunum) according to the Simcyp® 
scaling factor 2.04, an estimated Vmax value 502 µg/min is obtained.  
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In order to correctly simulate aliskiren plasma concentrations using the experimental Km 
value (2.89 µg/ml), the estimated in vivo value for Vmax (502 µg/min) could not be used. 
Instead,  Vmax had to be increased roughly 100-fold (50000 µg/min) (Table 6).  
Simulations with Vmax 500 µg/min resulted in the same plasma concentrations as was 
simulated without active efflux (Cmax 1800 ng/ml), suggesting that no active efflux 
occurs. This indicates that the drug concentration in enterocytes in the model is too low 
for effective efflux and does not reflect the in vitro or in vivo situation. 
 
In theory, the absorption area is larger in the apical membrane of the enterocyte due to 
the intestinal microvilli. This approach was tested in order to slow down the basolateral 
permeability of aliskiren in the model. The surface area (A) of the basolateral 
membrane of the enterocyte compartment was reduced to 1/10 and 1/100. In the model 
with MDR1 efflux, 1/10 basolateral surface area resulted in reduction of Cmax by half 
(120 ng/ml) when the increased drug concentration in the enterocyte accelerated the 
efflux (Table 6). In the model without active efflux, 1/10 basolateral surface area did 
not have an effect on Cmax, only1/100 surface area reduced Cmax to 1240 ng/ml.  
 
After a single dose of 150 mg aliskiren administrated during a treatment with potent 
MDR1 inhibitor itraconazole, aliskiren average Cmax 766 ± 377 ng/ml was reported 
(Tapaninen et al. 2010a). This suggests a great increase in the oral bioavailability of 
aliskiren, at least partly due to inhibition of active efflux by MDR1 in the intestine. In 
the model, this situation was simulated without MDR1 efflux. 300 mg dose resulted in 
Cmax 1880 ng/ml (Table 6), which may reflect to the in vivo situation with a potent 
MDR1 inhibitor, considering that in vivo Cmax 766 ng/ml was reached after a 150 mg 
dose. In the future, implementation of kinetic in vitro inhibition parameters (IC50, Ki) to 
predict the extent of a drug-drug interaction would be of great value.  
 
5.2.2 Considerations 
 
In the model, the drug is assumed evenly distributed in the enterocyte. In vivo, MDR1 is 
located in the membrane (cytoplasmic leaflet of the lipid bilayer (Shapiro and Ling 
1997)). A lipophilic substrate is likely more distributed in the membrane, as a 
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hydrophilic substrate is more distributed in the intracellular aqueous phase, where the 
volume is also larger. This suggests that for effective efflux, hydrophilic substrates need 
to have higher affinity to the transporter (Km) due to lower concentration in the binding 
site.  For lipophilic substrates, a weaker affinity can result in transport as effective. 
 
Expression of the MDR1 transporter has been shown to increase along the GI tract 
having the highest expression in the colon (Mouly et al., 2003; Thorn et al., 2005). In a 
more advanced model, a correlation factor could be used for the different compartments 
of the gastrointestinal tract. Because aliskiren is poorly metabolized, the effect of 
intestinal CYP3A4 is postulated to be a smaller contributor to the poor bioavailability 
and thus, was not included in the model. It has been suggested however, that substrates 
notably effluxed by MDR1 are more exposed to metabolism due to reabsorption into the 
enterocytes after efflux (Cummings et al., 2001). In further studies, it would be 
interesting to see if the contribution of intestinal CYP3A4 could be estimated by 
pharmacokinetic modeling. Opposite to MDR1, CYP3A4 expression is highest in the 
duodenum in vivo (Thorn et al., 2005).  
 
Pharmacokinetics of aliskiren have showed great inter-individual variability 
(Waldmeier et al., 2007; Tapaninen et al. 2010a). This may be, at least partly, 
contributed by inter-individual variation in the expression of intestinal MDR1. However, 
it is not been clarified what are factors influencing MDR1 expression and to what extent. 
Genetic variability in the ABCB1 gene has been suggested, but the common haplotypes 
c.1236C-c.2677G-c.3435C (CGC) and c.1236T-c.2677T-c3435T (TTT) showed no 
effect on the pharmacodynamics or pharmacokinetics of aliskiren (Tapaninen et al. 
2010b). The researchers suggested that the large variability may be explained by 
variability in the gastronintestinal physiology and other factors affecting the activity of 
MDR1 or CYP3A4, or other transporters of enzymes involved. In addition, aliskiren 
showed similar pharmacokinetics and pharmacodynamics in healthy Japanese and 
Caucasian subjects, although the pharmacokinetic parameters of both groups showed 
notable variation (Vaidyanathan et al. 2006). If these individualities could be explained 
and predicted, pharmacokinetic modeling could be a prospective tool in estimating an 
individual drug dose in clinical practice.  In addition,  
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5.3 Comparison of aliskiren and digoxin as MDR1 probes 
 
Digoxin is widely used and generally most recommended probe substrate in studying 
MDR1-mediated drug-drug interactions (Keogh and Kunta 2006; Rautio et al., 2006). 
Interactions with digoxin are clinically relevant due to its narrow therapeutic index, that 
may lead to drug induced toxicity. Clinical relevance enables the study of in vitro-in 
vivo correlations and establishment of predictive models. Neither aliskiren nor digoxin 
is exposed to significant CYP metabolism. The difference is that digoxin is eliminated 
mainly via kidney by excretion of unchanged digoxin into urine, as aliskiren’s 
elimination occurs mainly via hepato-biliary route to feces. MDR1 is responsible for the 
active secretion of digoxin in the renal tubular cells (de Lannoy and Silverman, 1992), 
thus inhibitors of MDR1 potentially affect the elimination of digoxin as well. 
 
The interaction between aliskiren and itraconazole in vivo in humans seems to be more 
pronounced than the interaction of digoxin and itraconazole. The serum concentrations 
of digoxin increased about 2-fold, when a therapeutic dose of intraconazole was given 
simultaneously with digoxin for 10 days (Partanen et al., 1996). However, inhibitor was 
given simultaneously instead of giving it first. Itraconazole decreased the renal 
clearance of digoxin most likely due to inhibition of MDR1-mediated active secretion in 
the kidney, which only partly explains the increase in serum concentrations of digoxin 
(Jalava et al., 1997). Inhibition of MDR1 in small intestine increasing the bioavailability 
of digoxin likely contributes to the increased serum concentration.  
 
Aliskiren does not have a narrow therapeutic index similar to digoxin, but on the other 
hand it makes aliskiren more safe probe to study MDR1-mediated interactions in 
humans. Aliskiren is classified as a class III compound according to the 
Biopharmaceutics Classification System (Drugs@FDA), having high solubility and low 
permeability. Digoxin is highly permeable and poorly soluble, classified as class II 
compound in the BCS system. Inhibition data obtained with digoxin may be applied to 
other MDR1 substrates similar to digoxin. On the other hand, inhibition data obtained 
with aliskiren could be applied to MDR1 substrates similar to aliskiren (wide 
therapeutic index, poor permeability). It has been suggested however, that due to 
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multiple binding sites of MDR1, different probes binding to different sites of MDR1 
would be needed for the characterization of interactions. For further studies, it would be 
interesting to compare the in vitro interactions of digoxin and aliskiren as probes with 
well characterized inhibitors (e.g. itraconazole, ketoconazole and verapamil).  
 
FDA has presented criteria for preferred in vitro MDR1 probe substrates and inhibitors 
in draft guidance for drug interaction studies (2006) (Table 9). However, a substrate or 
inhibitor that meets all the criteria has not been identified, instead a list of acceptable 
substrates, inhibitors and concentrations used is suggested. 
 
Criteria for preferred in vitro MDR1 probe substrates: 
1. Selective for the MDR1 transporter 
2. Exhibits low to moderate passive permeability (2 – 30 x 10-6 cm/s) 
3. No significant metabolism1 
4. Commercially available1 
5. May be used as an in vivo MDR1 probe substrate1 
1 
Optional 
 
 
6 CONCLUSIONS 
 
The objective of the experimental part was to study the MDR1-mediated transport of 
aliskiren and the related drug-drug interactions in vitro and in silico. MDR1-mediated 
transport of aliskiren in vesicular transport assay showed high affinity to the transporter, 
similar to what was reported previously in different assay systems. Aliskiren has been 
shown to be sensitive to MDR1 inhibition in vivo by potent MDR1 inhibitor 
itraconazole and the interaction in vitro was consistent. In addition, hydroxyitraconazole, 
itraconazole’s active metabolite formed in the intestine, was shown to be a potent 
inhibitor of MDR1-mediated transport of aliskiren in vitro. This suggests that 
hydroxyitraconazole may contribute to the interaction in vivo. However, the results are 
preliminary and more standardization of the test circumstances is needed. Due to time 
limitations, only a simple pharmacokinetic model was tested to describe the intestinal 
absorption of aliskiren. The integration of kinetic parameters (Km) from in vitro studies 
requires further optimization on how to describe the intracellular drug concentrations.  
Table 9. Criteria for preferred in vitro MDR1 probe substrates (FDA 2006) 
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 APPENDIX I 
 
 
 
 
Actively_transported(t) = Actively_transported(t - dt) + (Active_efflux) * dt 
INIT Actively_transported = 0 
 
INFLOWS: 
Active_efflux = 
MDR1_1+MDR1_2+MDR1_3+MDR1_4+MDR1_5+MDR1_6+MDR1_7 
AUC(t) = AUC(t - dt) + (AUC_laskuri) * dt 
INIT AUC = 0 
 
INFLOWS: 
AUC_laskuri = C_plasma 
Central(t) = Central(t - dt) + (True_absorption_rate - Elimination_rate) * dt 
INIT Central = 0 
 
INFLOWS: 
Gut Solid drug S1 Gut Dissolv ed drug D1 Enterocy te E1
Kd1
Permeation into enterocy teP1
Portal v ein
Absorption f rom intestine A1
Kd
Activ ely  transported
V2 cell
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Stomach Solid drug Stomach Dissolv ed drug
S2
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S4
S5
S6
S7
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E3
E4
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Kt14
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 True_absorption_rate = 
Fraction_avoiding_first_pass_metabolism*Drug_transfer_in_portal_vein 
OUTFLOWS: 
Elimination_rate = Kel*Central 
Colon(t) = Colon(t - dt) + (Kt7 + Kt14) * dt 
INIT Colon = 0 
 
INFLOWS: 
Kt7 = S7*Kt 
Kt14 = D7*Kt 
D2(t) = D2(t - dt) + (Kd2 + Kt8 + MDR1_2 - Kt9 - P2) * dt 
INIT D2 = 0 
 
INFLOWS: 
Kd2 = S2*Kd 
Kt8 = Gut_Dissolved_drug_D1*Kt 
MDR1_2 = (Vmax*C2b)/(Km+C2b) 
OUTFLOWS: 
Kt9 = D2*Kt 
P2 = A_solukalvo*0.00451*2*(C1b-C2b) 
D3(t) = D3(t - dt) + (Kd3 + MDR1_3 + Kt9 - P3 - Kt10) * dt 
INIT D3 = 0 
 
INFLOWS: 
Kd3 = S3*Kd 
MDR1_3 = (Vmax*C2c)/(Km+C2c) 
Kt9 = D2*Kt 
OUTFLOWS: 
P3 = A_solukalvo*0.00451*2*(C1c-C2c) 
Kt10 = D3*Kt 
D4(t) = D4(t - dt) + (Kd4 + MDR1_4 + Kt10 - P4 - Kt11) * dt 
INIT D4 = 0 
 
INFLOWS: 
Kd4 = S4*Kd 
MDR1_4 = (Vmax*C2d)/(Km+C2d) 
Kt10 = D3*Kt 
OUTFLOWS: 
P4 = A_solukalvo*0.00451*2*(C1d-C2d) 
Kt11 = D4*Kt 
D5(t) = D5(t - dt) + (Kd5 + MDR1_5 + Kt11 - P5 - Kt12) * dt 
INIT D5 = 0 
 
INFLOWS: 
Kd5 = S5*Kd 
MDR1_5 = (Vmax*C2e)/(Km+C2e) 
Kt11 = D4*Kt 
OUTFLOWS: 
 P5 = A_solukalvo*0.00451*2*(C1e-C2e) 
Kt12 = D5*Kt 
D6(t) = D6(t - dt) + (Kd6 + MDR1_6 + Kt12 - P6 - Kt13) * dt 
INIT D6 = 0 
 
INFLOWS: 
Kd6 = S6*Kd 
MDR1_6 = (Vmax*C2f)/(Km+C2f) 
Kt12 = D5*Kt 
OUTFLOWS: 
P6 = A_solukalvo*0.00451*2*(C1f-C2f) 
Kt13 = D6*Kt 
D7(t) = D7(t - dt) + (MDR1_7 + Kd7 + Kt13 - Kt14 - P7) * dt 
INIT D7 = 0 
 
INFLOWS: 
MDR1_7 = (Vmax*C2g)/(Km+C2g) 
Kd7 = S7*Kd 
Kt13 = D6*Kt 
OUTFLOWS: 
Kt14 = D7*Kt 
P7 = A_solukalvo*0.00451*2*(C1g-C2g) 
Drug_lost_in_first_pass_metabolism(t) = Drug_lost_in_first_pass_metabolism(t - dt) + 
(First_pass_metabolism_rate) * dt 
INIT Drug_lost_in_first_pass_metabolism = 0 
 
INFLOWS: 
First_pass_metabolism_rate = Hepatic_extraction_ratio*Drug_transfer_in_portal_vein 
E2(t) = E2(t - dt) + (P2 - A2 - MDR1_2) * dt 
INIT E2 = 0 
 
INFLOWS: 
P2 = A_solukalvo*0.00451*2*(C1b-C2b) 
OUTFLOWS: 
A2 = A_solukalvo_b*0.00451*2*C2b 
MDR1_2 = (Vmax*C2b)/(Km+C2b) 
E3(t) = E3(t - dt) + (P3 - A3 - MDR1_3) * dt 
INIT E3 = 0 
 
INFLOWS: 
P3 = A_solukalvo*0.00451*2*(C1c-C2c) 
OUTFLOWS: 
A3 = A_solukalvo_b*0.00451*2*C2c 
MDR1_3 = (Vmax*C2c)/(Km+C2c) 
E4(t) = E4(t - dt) + (P4 - A4 - MDR1_4) * dt 
INIT E4 = 0 
 
INFLOWS: 
 P4 = A_solukalvo*0.00451*2*(C1d-C2d) 
OUTFLOWS: 
A4 = A_solukalvo_b*0.00451*2*C2d 
MDR1_4 = (Vmax*C2d)/(Km+C2d) 
E5(t) = E5(t - dt) + (P5 - A5 - MDR1_5) * dt 
INIT E5 = 0 
 
INFLOWS: 
P5 = A_solukalvo*0.00451*2*(C1e-C2e) 
OUTFLOWS: 
A5 = A_solukalvo_b*0.00451*2*C2e 
MDR1_5 = (Vmax*C2e)/(Km+C2e) 
E6(t) = E6(t - dt) + (P6 - A6 - MDR1_6) * dt 
INIT E6 = 0 
 
INFLOWS: 
P6 = A_solukalvo*0.00451*2*(C1f-C2f) 
OUTFLOWS: 
A6 = A_solukalvo_b*0.00451*2*C2f 
MDR1_6 = (Vmax*C2f)/(Km+C2f) 
E7(t) = E7(t - dt) + (P7 - A7 - MDR1_7) * dt 
INIT E7 = 0 
 
INFLOWS: 
P7 = A_solukalvo*0.00451*2*(C1g-C2g) 
OUTFLOWS: 
A7 = A_solukalvo_b*0.00451*2*C2g 
MDR1_7 = (Vmax*C2g)/(Km+C2g) 
Eliminated(t) = Eliminated(t - dt) + (Elimination_rate) * dt 
INIT Eliminated = 0 
 
INFLOWS: 
Elimination_rate = Kel*Central 
Enterocyte_E1(t) = Enterocyte_E1(t - dt) + (Permeation_into_enterocyteP1 - 
Absorption_from_intestine_A1 - MDR1_1) * dt 
INIT Enterocyte_E1 = 0 
 
INFLOWS: 
Permeation_into_enterocyteP1 = A_solukalvo*0.00451*2*(C1_lumen-C2_cell) 
OUTFLOWS: 
Absorption_from_intestine_A1 = A_solukalvo_b*0.00451*2*C2_cell 
MDR1_1 = (Vmax*C2_cell)/(Km+C2_cell) 
First_pass_liver(t) = First_pass_liver(t - dt) + (Drug_transfer_in_portal_vein - 
True_absorption_rate - First_pass_metabolism_rate) * dt 
INIT First_pass_liver = 0 
 
INFLOWS: 
 Drug_transfer_in_portal_vein = 
A2+A3+A4+A5+A6+A7+Absorption_from_intestine_A1 
OUTFLOWS: 
True_absorption_rate = 
Fraction_avoiding_first_pass_metabolism*Drug_transfer_in_portal_vein 
First_pass_metabolism_rate = Hepatic_extraction_ratio*Drug_transfer_in_portal_vein 
Gut_Dissolved_drug_D1(t) = Gut_Dissolved_drug_D1(t - dt) + (Kd1 + Transfer_Kt + 
MDR1_1 - Kt8 - Permeation_into_enterocyteP1) * dt 
INIT Gut_Dissolved_drug_D1 = 0 
 
INFLOWS: 
Kd1 = Gut_Solid_drug_S1*Kd 
Transfer_Kt = Stomach_Dissolved_drug*Kge 
MDR1_1 = (Vmax*C2_cell)/(Km+C2_cell) 
OUTFLOWS: 
Kt8 = Gut_Dissolved_drug_D1*Kt 
Permeation_into_enterocyteP1 = A_solukalvo*0.00451*2*(C1_lumen-C2_cell) 
Gut_Solid_drug_S1(t) = Gut_Solid_drug_S1(t - dt) + (GE - Kd1 - Kt1) * dt 
INIT Gut_Solid_drug_S1 = 0 
 
INFLOWS: 
GE = 4250 
OUTFLOWS: 
Kd1 = Gut_Solid_drug_S1*Kd 
Kt1 = Gut_Solid_drug_S1*Kt 
Noname_3(t) = Noname_3(t - dt) + (Passive_transport) * dt 
INIT Noname_3 = 0 
 
INFLOWS: 
Passive_transport = P2+P3+P4+P5+P6+P7+Permeation_into_enterocyteP1 
Portal_vein(t) = Portal_vein(t - dt) + (Absorption_from_intestine_A1 + A2 + A3 + A4 + 
A5 + A6 + A7 - Drug_transfer_in_portal_vein) * dt 
INIT Portal_vein = 0 
 
INFLOWS: 
Absorption_from_intestine_A1 = A_solukalvo_b*0.00451*2*C2_cell 
A2 = A_solukalvo_b*0.00451*2*C2b 
A3 = A_solukalvo_b*0.00451*2*C2c 
A4 = A_solukalvo_b*0.00451*2*C2d 
A5 = A_solukalvo_b*0.00451*2*C2e 
A6 = A_solukalvo_b*0.00451*2*C2f 
A7 = A_solukalvo_b*0.00451*2*C2g 
OUTFLOWS: 
Drug_transfer_in_portal_vein = 
A2+A3+A4+A5+A6+A7+Absorption_from_intestine_A1 
S2(t) = S2(t - dt) + (Kt1 - Kt2 - Kd2) * dt 
INIT S2 = 0 
 
 INFLOWS: 
Kt1 = Gut_Solid_drug_S1*Kt 
OUTFLOWS: 
Kt2 = S2*Kt 
Kd2 = S2*Kd 
S3(t) = S3(t - dt) + (Kt2 - Kt3 - Kd3) * dt 
INIT S3 = 0 
 
INFLOWS: 
Kt2 = S2*Kt 
OUTFLOWS: 
Kt3 = S3*Kt 
Kd3 = S3*Kd 
S4(t) = S4(t - dt) + (Kt3 - Kt4 - Kd4) * dt 
INIT S4 = 0 
 
INFLOWS: 
Kt3 = S3*Kt 
OUTFLOWS: 
Kt4 = S4*Kt 
Kd4 = S4*Kd 
S5(t) = S5(t - dt) + (Kt4 - Kt5 - Kd5) * dt 
INIT S5 = 0 
 
INFLOWS: 
Kt4 = S4*Kt 
OUTFLOWS: 
Kt5 = S5*Kt 
Kd5 = S5*Kd 
S6(t) = S6(t - dt) + (Kt5 - Kt6 - Kd6) * dt 
INIT S6 = 0 
 
INFLOWS: 
Kt5 = S5*Kt 
OUTFLOWS: 
Kt6 = S6*Kt 
Kd6 = S6*Kd 
S7(t) = S7(t - dt) + (Kt6 - Kd7 - Kt7) * dt 
INIT S7 = 0 
 
INFLOWS: 
Kt6 = S6*Kt 
OUTFLOWS: 
Kd7 = S7*Kd 
Kt7 = S7*Kt 
Stomach_Dissolved_drug(t) = Stomach_Dissolved_drug(t - dt) + (Dissolution_Kd - 
Transfer_Kt) * dt 
INIT Stomach_Dissolved_drug = 0 
  
INFLOWS: 
Dissolution_Kd = Stomach_Solid_drug*Kd 
OUTFLOWS: 
Transfer_Kt = Stomach_Dissolved_drug*Kge 
Stomach_Solid_drug(t) = Stomach_Solid_drug(t - dt) + (- GE - Dissolution_Kd) * dt 
INIT Stomach_Solid_drug = 300000 
 
OUTFLOWS: 
GE = 4250 
Dissolution_Kd = Stomach_Solid_drug*Kd 
A_solukalvo = 2857 
A_solukalvo_b = 28.57 
Ba = Central/300000 
C_plasma = Central/Vd 
C1_lumen = Gut_Dissolved_drug_D1/V1 
C1b = D2/V1 
C1c = D3/V1 
C1d = D4/V1 
C1e = D5/V1 
C1f = D6/V1 
C1g = D7/V1 
C2_cell = Enterocyte_E1/V2_cell 
C2b = E2/V2_cell 
C2c = E3/V2_cell 
C2d = E4/V2_cell 
C2e = E5/V2_cell 
C2f = E6/V2_cell 
C2g = E7/V2_cell 
Fraction_avoiding_first_pass_metabolism = 1-Hepatic_extraction_ratio 
Hepatic_extraction_ratio = 0.10 
Kd = 0.0317 
Kel = (4.873*10^-4) 
Kge = 0.0583 
Km = 2.79 
Kt = 0.035 
V1 = 35.7 
V2_cell = 2.86 
Vd = 135000 
Vmax = 50000 
